

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/031866

International filing date: 29 September 2004 (29.09.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/506,805
Filing date: 29 September 2003 (29.09.2003)

Date of receipt at the International Bureau: 06 December 2004 (06.12.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

November 29, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/506,805

FILING DATE: *September 29, 2003*

RELATED PCT APPLICATION NUMBER: *PCT/US04/31866*

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office



PROVISIONAL APPLICATION FOR PATENT COVER SHEET
This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).
Express Mail Label No. EL983811967

INVENTOR(S)						
Given Name (first and middle [if any]) Mahin D.		Family Name or Surname Maines		Residence (City and either State or Foreign Country) 235 Huntington Hills Rochester, NY 14622		
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto						
TITLE OF THE INVENTION (280 characters max) METHODS OF MODULATING CELL CYCLE AND CELL SIGNALING PATHWAYS USING BILIVERDIN REDUCTASE						
Direct all correspondence to: <input type="checkbox"/> Customer Number _____ → Place Customer Number Bar Code Label here						
OR Type Customer Number here						
<input checked="" type="checkbox"/> Firm or Individual Name		Nixon Peabody LLP				
Address		Clinton Square, P.O. Box 31051				
Address						
City		Rochester	State	NY	ZIP	14603-1051
Country		USA	Telephone	(585) 263-1128	Fax	(585) 263-1600
ENCLOSED APPLICATION PARTS (check all that apply)						
<input checked="" type="checkbox"/> Specification		Number of Pages	87	<input type="checkbox"/> CD(s), Number		
<input type="checkbox"/> Drawing(s)		Number of Sheets		<input type="checkbox"/> Other (specify)		
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76						
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT						
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE		
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees				AMOUNT (\$)		
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge fees which may be required, or credit any overpayment to Deposit Account Number: 14-1138				\$80.00		
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.						
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.						
<input type="checkbox"/> No.						
<input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: NIH ES04066						

Respectfully submitted,

Date 09/29/03

SIGNATURE Edwin V. Merkel

REGISTRATION NO.
(if appropriate)

40,087

TYPED or PRINTED NAME Edwin V. Merkel

Docket Number:

176/61620 (1251)

TELEPHONE (585) 263-1128

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

Mail Stop Provisional Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE TRANSMITTAL FOR FY 2003

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 80

Complete if Known

Application Number

Filing Date

First Named Inventor

Mahin D. Maines

Examiner Name

Art Unit

Attorney Docket No.

176/61620 (1251/1208)

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☐ Deposit Account:

Deposit Account Number 14-1138

Deposit Account Name Nixon Peabody LLP

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	80

SUBTOTAL (1) (\$ 80

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
-20** =	X		0
Independent Claims	-3** =	X	0
Multiple Dependent	X		0

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 0

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description
1051	130	2051	65	Surcharge - late filing fee or oath
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet
1053	130	1053	130	Non-English specification
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action
1251	110	2251	55	Extension for reply within first month
1252	410	2252	205	Extension for reply within second month
1253	930	2253	465	Extension for reply within third month
1254	1,450	2254	725	Extension for reply within fourth month
1255	1,970	2255	985	Extension for reply within fifth month
1401	320	2401	160	Notice of Appeal
1402	320	2402	160	Filing a brief in support of an appeal
1403	280	2403	140	Request for oral hearing
1451	1,510	1451	1,510	Petition to institute a public use proceeding
1452	110	2452	55	Petition to revive - unavoidable
1453	1,300	2453	650	Petition to revive - unintentional
1501	1,300	2501	650	Utility issue fee (or reissue)
1502	470	2502	235	Design issue fee
1503	630	2503	315	Plant issue fee
1460	130	1460	130	Petitions to the Commissioner
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)
1806	180	1806	180	Submission of Information Disclosure Stmt
8021	40	8021	40	Recording each patent assignment per property (times number of properties)
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))
1810	750	2810	375	For each additional invention to be examined (37 CFR 1.129(b))
1801	750	2801	375	Request for Continued Examination (RCE)
1802	900	1802	900	Request for expedited examination of a design application

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:

- ☐ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop _____, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450
- ☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) _____

Date

Signature

Typed or printed name

SUBMITTED BY

Name (Print/Type) Edwin V. Merkel

Signature

Edwin V. Merkel

Registration No. (Attorney/Agent)

40,087

Complete (if applicable)

Telephone (585) 263-1128

Date

September 29, 2003

SEND TO: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

EXPRESS MAIL CERTIFICATE

DOCKET NO.: **176/61620 (1251)**

APPLICANT: **Mahin D. Maines**

TITLE: **METHODS OF MODULATING CELL CYCLE AND CELL
SIGNALING PATHWAYS USING BILIVERDIN REDUCTASE**

Certificate is attached to the **Provisional Application for Patent Cover Sheet
and Fee Transmittal (2 pages)** of the above-identified application.

“EXPRESS MAIL” NUMBER: **EL983811967US**
DATE OF DEPOSIT: **September 29, 2003**

I hereby certify that this paper or fee is being deposited with the United States Postal Service
“Express Mail Post Office to Addressee” service under 37 CFR 1.10 on the date indicated
above and is addressed to Mail Stop Provisional Patent Application, Commissioner for
Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Shawn A. Lockett
(Typed or Printed Name of Person Mailing
Paper or Fee)


(Signature of Person Mailing Paper or Fee)

**TITLE: METHODS OF MODULATING CELL CYCLE AND
CELL SIGNALING PATHWAYS USING BILIVERDIN
REDUCTASE**

APPLICANT: Mahin D. Maines

DOCKET NO.: 176/61620 (1251)

PROVISIONAL PATENT APPLICATION

METHODS OF MODULATING CELL CYCLE AND CELL SIGNALING PATHWAYS USING BILIVERDIN REDUCTASE

5 The present invention was made, at least in part, with funding received
from the National Institutes of Health under grant ES04066. The U.S. government
may have certain rights in this invention.

FIELD OF THE INVENTION

10 The present invention relates generally to the use of biliverdin
reductase, or functional fragments or variants thereof, to modify the expression of cell
cycle and cell signaling pathways.

BACKGROUND OF THE INVENTION

15 Biliverdin reductase (hBVR) is a dual function enzyme that functions
both as a reductase and a kinase. BVR also functions as a transcription factor for
expression of the stress-responsive gene heme oxygenase 1. Using gene array
technology and flow cytometry, human kidney 293 cells transfected with an adenovirus
20 construct carrying hBVR, were examined for an effect of the overexpression of BVR
on cell cycle and cell signaling pathways. As a control, cells transfected with the same
construct but carrying reverse of hBVR gene were also tested.

DETAILED DESCRIPTION OF THE INVENTION

25 The present invention relates to the use of biliverdin reductase
("BVR") to regulate expression of cell cycle and cell signaling pathways. As a
consequence, by modifying the nuclear or cellular concentration of BVR, or
fragments or variants thereof, the expression of cell cycle and cell signaling proteins
30 can be regulated, i.e., either enhanced or suppressed.

To increase the nuclear or cellular concentration of BVR, or fragments
or variants thereof, either BVR or the fragments or variants thereof can be introduced
into the cell directly or expressed therein via *in vivo* cell transformation. To decrease

the nuclear concentration of BVR, antisense BVR RNA can be introduced into the cell directly or expressed therein via *in vivo* transformation, which antisense BVR RNA inhibits BVR mRNA translation. Thus, both protein or RNA delivery systems or gene delivery systems can be employed in the present invention.

5 As used herein, the terms biliverdin reductase and BVR refer to any mammalian BVR, but preferably human BVR ("hBVR").

One form of hBVR has an amino acid sequence corresponding to SEQ ID NO: 1 as follows:

10 Met Asn Ala Glu Pro Glu Arg Lys Phe Gly Val Val Val Val Gly Val
1 5 10 15
15 Gly Arg Ala Gly Ser Val Arg Met Arg Asp Leu Arg Asn Pro His Pro
20 25 30
Ser Ser Ala Phe Leu Asn Leu Ile Gly Phe Val Ser Arg Arg Glu Leu
35 40 45
20 Gly Ser Ile Asp Gly Val Gln Gln Ile Ser Leu Glu Asp Ala Leu Ser
50 55 60
Ser Gln Glu Val Glu Val Ala Tyr Ile Cys Ser Glu Ser Ser Ser His
65 70 75 80
25 Glu Asp Tyr Ile Arg Gln Phe Leu Asn Ala Gly Lys His Val Leu Val
85 90 95
Glu Tyr Pro Met Thr Leu Ser Leu Ala Ala Ala Gln Glu Leu Trp Glu
30 100 105 110
Leu Ala Glu Gln Lys Gly Lys Val Leu His Glu Glu His Val Glu Leu
115 120 125
35 Leu Met Glu Glu Phe Ala Phe Leu Lys Lys Glu Val Val Gly Lys Asp
130 135 140
Leu Leu Lys Gly Ser Leu Leu Phe Thr Ser Asp Pro Leu Glu Glu Asp
145 150 155 160
40 Arg Phe Gly Phe Pro Ala Phe Ser Gly Ile Ser Arg Leu Thr Trp Leu
165 170 175
Val Ser Leu Phe Gly Glu Leu Ser Leu Val Ser Ala Thr Leu Glu Glu
45 180 185 190
Arg Lys Glu Asp Gln Tyr Met Lys Met Thr Val Cys Leu Glu Thr Glu
195 200 205
50 Lys Lys Ser Pro Leu Ser Trp Ile Glu Glu Lys Gly Pro Gly Leu Lys
210 215 220

Arg Asn Arg Tyr Leu Ser Phe His Phe Lys Ser Gly Ser Leu Glu Asn
225 230 235 240

Val Pro Asn Val Gly Val Asn Lys Asn Ile Phe Leu Lys Asp Gln Asn
5 245 250 255

Ile Phe Val Gln Lys Leu Leu Gly Gln Phe Ser Glu Lys Glu Leu Ala
260 265 270

10 Ala Glu Lys Lys Arg Ile Leu His Cys Leu Gly Leu Ala Glu Glu Ile
275 280 285

Gln Lys Tyr Cys Cys Ser Arg Lys
290 295

15

Heterologous expression and isolation of hBVR is described in Maines et al., *Eur. J. Biochem.* 235(1-2):372-381 (1996); Maines et al., *Arch. Biochem. Biophys.* 300(1):320-326 (1993), each of which is hereby incorporated by reference in its entirety. A DNA molecule encoding this form of hBVR has a nucleotide sequence corresponding to SEQ

20 ID NO: 2 as follows:

ggggtggcgc cggagctgc acggagagcg tgcccgtcag tgaccgaaga agagaccaag 60
atgaatgcag agcccgagag gaagtttggc gtggtggtgg ttggtggtgg ccgagccggc 120
tccgtgcgga tgagggactt gcggaatcca cacccttcct cagcgttcct gaacctgatt 180
25 ggcttcgtgt cgagaaggga gctcgggagc attgatggag tccagcagat ttctttggag 240
gatgctcttt ccagccaaga ggtggaggtc gcctatatct gcagtgcagc ctccagccat 300
gaggactaca tcaggcagtt ccttaatgct ggcaagcacg tccttgtgga ataccccatg 360
acactgtcat tggcggcgcg tcaggaactg tgggagctgg ctgagcagaa aggaaaagtc 420
ttgcacgagg agcatgttga actcttgatg gaggaattcg ctttcctgaa aaaagaagtg 480
30 gtggggaaaag acctgctgaa agggtcgctc ctcttcacat ctgaccggtt ggaagaagac 540
cggtttggct tccctgcatt cagcggcatc tctcgactga cctggctggt ctccctcttt 600
ggggagcttt ctcttgtgtc tgccactttg gaagagcgaa aggaagatca gtatatgaaa 660
atgacagtgt gtctggagac agagaagaaa agtccactgt catggattga agaaaaagga 720
cctgggtctaa aacgaaacag atattttaagc ttccatttca agtctgggtc cttggagaat 780
35 gtgccaaatg taggagtga taagaacata tttctgaaag atcaaaatat atttgtccag 840
aaactcttgg gccagttctc tgagaaggaa ctggctgctg aaaagaaacg catcctgcac 900
tgccctggggc ttgcagaaga aatccagaaa tattgctggt caaggaagta agaggaggag 960
gtgatgtagc acttccaaga tggcaccagc atttggttct tctcaagagt tgaccattat 1020
ctctattctt aaaattaaac atgttgggga aacaaaaaaa aaaaaaaaaa 1070

The open reading frame which encodes hBVR of SEQ ID NO: 1 extends from nt 1 to nt 888.

Another form of hBVR has an amino acid sequence according to SEQ

5 ID NO: 3 as follows:

```
Met Asn Thr Glu Pro Glu Arg Lys Phe Gly Val Val Val Val Gly Val
  1              5              10              15

10 Gly Arg Ala Gly Ser Val Arg Met Arg Asp Leu Arg Asn Pro His Pro
    20              25              30

Ser Ser Ala Phe Leu Asn Leu Ile Gly Phe Val Ser Arg Arg Glu Leu
    35              40              45

15 Gly Ser Ile Asp Gly Val Gln Gln Ile Ser Leu Glu Asp Ala Leu Ser
    50              55              60

Ser Gln Glu Val Glu Val Ala Tyr Ile Cys Ser Glu Ser Ser Ser His
20  65              70              75              80

Glu Asp Tyr Ile Arg Gln Phe Leu Asn Ala Gly Lys His Val Leu Val
    85              90              95

25 Glu Tyr Pro Met Thr Leu Ser Leu Ala Ala Ala Gln Glu Leu Trp Glu
    100             105             110

Leu Ala Glu Gln Lys Gly Lys Val Leu His Glu Glu His Val Glu Leu
    115             120             125

30 Leu Met Glu Glu Phe Ala Phe Leu Lys Lys Glu Val Val Gly Lys Asp
    130             135             140

Leu Leu Lys Gly Ser Leu Leu Phe Thr Ala Gly Pro Leu Glu Glu Glu
35  145             150             155             160

Arg Phe Gly Phe Pro Ala Phe Ser Gly Ile Ser Arg Leu Thr Trp Leu
    165             170             175
```

```

Val Ser Leu Phe Gly Glu Leu Ser Leu Val Ser Ala Thr Leu Glu Glu
      180                      185                      190

Arg Lys Glu Asp Gln Tyr Met Lys Met Thr Val Cys Leu Glu Thr Glu
5      195                      200                      205

Lys Lys Ser Pro Leu Ser Trp Ile Glu Glu Lys Gly Pro Gly Leu Lys
      210                      215                      220

10 Arg Asn Arg Tyr Leu Ser Phe His Phe Lys Ser Gly Ser Leu Glu Asn
    225                      230                      235                      240

Val Pro Asn Val Gly Val Asn Lys Asn Ile Phe Leu Lys Asp Gln Asn
      245                      250                      255

15 Ile Phe Val Gln Lys Leu Leu Gly Gln Phe Ser Glu Lys Glu Leu Ala
    260                      265                      270

Ala Glu Lys Lys Arg Ile Leu His Cys Leu Gly Leu Ala Glu Glu Ile
20      275                      280                      285

Gln Lys Tyr Cys Cys Ser Arg Lys
    290                      295

```

25

This hBVR sequence is reported at Komuro et al., NCBI Accession No. G02066, direct submission to the EMBL Data Library (1998), which is hereby incorporated by reference in its entirety. Differences between the hBVR of SEQ ID NO: 1 and the hBVR of SEQ ID NO: 3 are at aa residues 3, 154, 155, and 160. Thus, residue 3 can be either alanine or threonine, residue 154 can be either alanine or serine, residue 155 can be either aspartic acid or glycine, and residue 160 can be either aspartic acid or glutamic acid.

30

In addition, BVR from other mammals, such as rat (rBVR), have been recombinantly expressed and isolated (Fakhrai et al., *J. Biol. Chem.* 267(6):4023-4029 (1992), which is hereby incorporated by reference in its entirety). The rBVR of shares about 82% aa identity to the hBVR of SEQ ID NO: 1, with variations in aa residues being highly conserved.

35

As described in greater detail in co-pending U.S. Patent Application Serial No. 09/606,129 to Maines, filed June 28, 2000 (which is hereby incorporated by reference in its entirety), BVR is characterized by an amazingly large number of functional domains and motifs, including without limitation: putative and/or

5 demonstrated phosphorylation sites from aa 15 to 20, aa 21 to 23, aa 44 to 46 or 47, aa 49 to 54, aa 58 to 61, aa 64 to 67, aa 78 to 81, aa 79 to 82, aa 189 to 192, aa 207 to 209, aa 214 to 217, aa 222 to 227, aa 236 to 241, aa 245 to 250, aa 267 to 269 or 270, and aa 294 to 296 of SEQ ID NO: 1; a basic N-terminal domain characterized by aa 6 to 8 of SEQ ID NO: 1; a hydrophobic domain characterized by aa 9 to 14 of SEQ ID NO: 1; a

10 nucleotide binding domain characterized by aa 15 to 20 of SEQ ID NO: 1; an oxidoreductase domain characterized by aa 90 to 97 of SEQ ID NO: 1; a leucine zipper spanning aa 129 to 157 of SEQ ID NO: 1; several kinase motifs, including aa 44 to 46, aa 147 to 149, and aa 162 to 164 of SEQ ID NO: 1; a nuclear localization signal spanning aa 222 to 228 of SEQ ID NO: 1; a myristylation site spanning aa 221 to 225

15 of SEQ ID NO: 1; a zinc finger domain spanning aa 280 to 293 of SEQ ID NO: 1; and several substrate binding domains.

Without being bound thereby, it is believed that BVR can induce changes in the expression levels of regulatory cell cycle and cell signaling proteins in one or more of several ways. First, because BVR has been shown to be a kinase, BVR

20 can regulate the activity of certain cell signaling molecules and, therefore, may indirectly modify expression levels of other cell cycle and cell signaling proteins. Second, BVR has been shown to regulate expression levels of proteins whose genes possess an AP-1 binding site in the upstream regulatory control regions, such as heme oxygenase. In this manner, BVR can directly increase expression of such genes

25 whereas BVR inhibition can decrease expression of such genes.

As used herein, BVR variants and fragments can be substituted for BVR either in whole or in part.

Fragments of BVR preferably contain the leucine-zipper motif as listed above and any suitable nuclear localization signal, including the nuclear localization

30 signal described above. Suitable fragments are capable of binding to the AP-1 binding site(s) in the promoter region of genes whose expression are to be modified, such as HO-1. Suitable fragments can be produced by several means.

Subclones of a gene encoding a known BVR can be produced using conventional molecular genetic manipulation for subcloning gene fragments, such as described by Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Springs Laboratory, Cold Springs Harbor, New York (1989), and Ausubel et al. (ed.), *Current*
5 *Protocols in Molecular Biology*, John Wiley & Sons (New York, NY) (1999 and preceding editions), each of which is hereby incorporated by reference in its entirety. The subclones then are expressed *in vitro* or *in vivo* in bacterial cells to yield a smaller protein or polypeptide that can be tested for a particular activity.

In another approach, based on knowledge of the primary structure of the
10 protein, fragments of a BVR gene may be synthesized using the PCR technique together with specific sets of primers chosen to represent particular portions of the protein. Erlich et al., *Science* 252:1643-51 (1991), which is hereby incorporated by reference in its entirety. These can then be cloned into an appropriate vector for expression of a truncated protein or polypeptide from bacterial cells as described
15 above. For example, oligomers of at least about 15 to 20 nt in length can be selected from the nucleic acid molecules of SEQ ID NO: 2 for use as primers.

In addition, chemical synthesis can also be employed using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, *J. Am. Chem. Assoc.* 85:2149-2154 (1964), which is hereby incorporated by reference in
20 its entirety) or synthesis in homogenous solution (Houbenweyl, *Methods of Organic Chemistry*, ed. E. Wansch, Vol. 15, I and II, Thieme, Stuttgart (1987), which is hereby incorporated by reference in its entirety).

Exemplary fragments include N-terminal, internal, and C-terminal fragments that possess a functional leucine zipper motif alone or in combination with
25 other motifs, such as a nuclear localization signal.

Variants of suitable BVR proteins or polypeptides can also be expressed. Variants may be made by, for example, the deletion, addition, or alteration of amino acids that have either (i) minimal influence on certain properties, secondary structure, and hydropathic nature of the polypeptide or (ii) substantial effect on one or
30 more properties of BVR. Variants of BVR can also be fragments of BVR that include one or more deletion, addition, or alteration of amino acids of the type described above. The BVR variant preferably contains a deletion, addition, or alteration of amino acids within one of the above-listed functional domains. The substituted or additional

amino acids can be either L-amino acids, D-amino acids, or modified amino acids, preferably L-amino acids. Whether a substitution, addition, or deletion results in modification of BVR variant activity may depend, at least in part, on whether the altered amino acid is conserved. Conserved amino acids can be grouped either by molecular weight or charge and/or polarity of R groups, acidity, basicity, and presence of phenyl groups, as is known in the art.

Exemplary variants include the protein or polypeptides of SEQ. ID. Nos. 1 and 3, which have single or multiple amino acid residue substitutions, including, without limitation, SEQ ID NO: 1 as modified by one or more of the following variations: (i) Gly¹⁷ Ala within the nucleotide binding domain, (ii) Ser⁴⁴ Ala within one of the kinase motifs, (iii) Cys⁷⁴ Ala within a substrate binding domain, (iv) Lys⁹²His⁹³ Ala-Ala within the oxidoreductase motif, (v) G²²²LKRNR²²⁷ VIGSTG within the nuclear localization signal, and (vi) Cys²⁸¹ Ala within the zinc finger domain, and Lys²⁹⁶ Ala at the C terminus within a substrate binding domain (i.e., protein kinase inhibitory domain).

Variants may also include, for example, a polypeptide conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification, identification, or therapeutic use (i.e., delivery) of the polypeptide.

Another variant type of BVR is a fusion polypeptide that includes a fragment of BVR containing the functional leucine zipper motif (but not the endogenous nuclear localization signal) and a functional nuclear localization signal. The fusion protein can be expressed or synthesized using known techniques in the art. A number of nuclear localization signals have been identified in the art and can be utilized in combination with the fragment of BVR to obtain the fusion protein, which is targeted for uptake into the cell nucleus following its introduction into the cell whose cell cycle or cell signaling pathways are to be modified in accordance with the present invention. Production of chimeric genes encoding such fusion proteins can be carried out as described *infra*.

The BVR protein or polypeptide (or fragment or variant thereof) can be recombinantly produced, isolated, and then purified, if necessary. When recombinantly produced, the biliverdin reductase protein or polypeptide (or fragment or variant

thereof) is expressed in a recombinant host cell, typically, although not exclusively, a prokaryote.

When a prokaryotic host cell is selected for subsequent transformation, the promoter region used to construct the recombinant DNA molecule (i.e., transgene) should be appropriate for the particular host. The DNA sequences of eukaryotic promoters, as described *infra* for expression in eukaryotic host cells, differ from those of prokaryotic promoters. Eukaryotic promoters and accompanying genetic signals may not be recognized in or may not function in a prokaryotic system, and, further, prokaryotic promoters are not recognized and do not function in eukaryotic cells.

Similarly, translation of mRNA in prokaryotes depends upon the presence of the proper prokaryotic signals which differ from those of eukaryotes. Efficient translation of mRNA in prokaryotes requires a ribosome binding site called the Shine-Dalgarno ("SD") sequence on the mRNA. This sequence is a short nucleotide sequence of mRNA that is located before the start codon, usually AUG, which encodes the amino-terminal methionine of the protein. The SD sequences are complementary to the 3'-end of the 16S rRNA (ribosomal RNA) and probably promote binding of mRNA to ribosomes by duplexing with the rRNA to allow correct positioning of the ribosome. For a review on maximizing gene expression, see Roberts and Lauer, *Methods in Enzymology*, 68:473 (1979), which is hereby incorporated by reference in its entirety.

Promoters vary in their "strength" (i.e., their ability to promote transcription). For the purposes of expressing a cloned gene, it is desirable to use strong promoters in order to obtain a high level of transcription and, hence, expression of the gene. Depending upon the host cell system utilized, any one of a number of suitable promoters may be used. For instance, when cloning in *E. coli*, its bacteriophages, or plasmids, promoters such as the T7 phage promoter, *lac* promoter, *trp* promoter, *recA* promoter, ribosomal RNA promoter, the P_R and P_L promoters of coliphage lambda and others, including but not limited, to *lacUV5*, *ompF*, *bla*, *lpp*, and the like, may be used to direct high levels of transcription of adjacent DNA segments. Additionally, a hybrid *trp-lacUV5* (*tac*) promoter or other *E. coli* promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted gene.

Bacterial host cell strains and expression vectors may be chosen which inhibit the action of the promoter unless specifically induced. In certain operons, the addition of specific inducers is necessary for efficient transcription of the inserted DNA. For example, the *lac* operon is induced by the addition of lactose or IPTG (isopropylthio-beta-D-galactoside). A variety of other operons, such as *trp*, *pro*, etc., are under different controls.

Specific initiation signals are also required for efficient gene transcription and translation in prokaryotic cells. These transcription and translation initiation signals may vary in "strength" as measured by the quantity of gene specific messenger RNA and protein synthesized, respectively. The DNA expression vector, which contains a promoter, may also contain any combination of various "strong" transcription and/or translation initiation signals. For instance, efficient translation in *E. coli* requires a Shine-Dalgarno ("SD") sequence about 7-9 bases 5' to the initiation codon ("ATG") to provide a ribosome binding site. Thus, any SD-ATG combination that can be utilized by host cell ribosomes may be employed. Such combinations include, but are not limited to, the SD-ATG combination from the *cro* gene or the *N* gene of coliphage lambda, or from the *E. coli* tryptophan E, D, C, B or A genes. Additionally, any SD-ATG combination produced by recombinant DNA or other techniques involving incorporation of synthetic nucleotides may be used.

Mammalian cells can also be used to recombinantly produce BVR or fragments or variants thereof. Mammalian cells suitable for carrying out the present invention include, among others: COS (e.g., ATCC No. CRL 1650 or 1651), BHK (e.g., ATCC No. CRL 6281), CHO (ATCC No. CCL 61), HeLa (e.g., ATCC No. CCL 2), 293 (ATCC No. 1573), CHOP, and NS-1 cells.

Suitable expression vectors for directing expression in mammalian cells generally include a promoter, as well as other transcription and translation control sequences known in the art. Common promoters include SV40, MMTV, metallothionein-1, adenovirus Ela, CMV, immediate early, immunoglobulin heavy chain promoter and enhancer, and RSV-LTR.

Regardless of the selection of host cell, once the DNA molecule coding for a biliverdin reductase protein or polypeptide, or fragment or variant thereof, has been ligated to its appropriate regulatory regions (or chimeric portions) using well known molecular cloning techniques, it can then be introduced into a suitable vector or

otherwise introduced directly into a host cell using transformation protocols well known in the art (Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Press, NY (1989), which is hereby incorporated by reference in its entirety).

5 When an expression vector is used for purposes of *in vivo* transformation to induce or inhibit of BVR expression in a target cell, promoters of varying strength can be employed depending on the degree of enhancement or suppression desired. One of skill in the art can readily select appropriate mammalian promoters based on their strength as a promoter. Alternatively, an inducible promoter can be employed for
10 purposes of controlling when expression or suppression of BVR is desired. One of skill in the art can readily select appropriate inducible mammalian promoters from those known in the art. Finally, tissue specific mammalian promoters can be selected to restrict the efficacy of any gene transformation system to a particular tissue. Tissue specific promoters are known in the art and can be selected based upon the tissue or cell
15 type to be treated.

 The recombinant molecule can be introduced into host cells via transformation, particularly transduction, conjugation, mobilization, or electroporation. Suitable host cells include, but are not limited to, bacteria, virus, yeast, mammalian cells, insect, plant, and the like. The host cells, when grown in an appropriate medium,
20 are capable of expressing the biliverdin reductase, or fragment or variant thereof, which can then be isolated therefrom and, if necessary, purified. The biliverdin reductase, or fragment or variant thereof, is preferably produced in purified form (preferably at least about 60%, more preferably 80%, pure) by conventional techniques.

 A further aspect of the present invention relates to an antisense nucleic
25 acid molecule capable of hybridizing with an RNA transcript coding for BVR. Basically, the antisense nucleic acid is expressed from a transgene which is prepared by ligation of a DNA molecule, coding for BVR, or a fragment or variant thereof, into an expression vector in reverse orientation with respect to its promoter and 3' regulatory sequences. Upon transcription of the DNA molecule, the resulting RNA molecule will
30 be complementary to the mRNA transcript coding for the actual protein or polypeptide product. Ligation of DNA molecules in reverse orientation can be performed according to known techniques which are standard in the art.

Such antisense nucleic acid molecules of the invention may be used in gene therapy to treat or prevent various disorders. For a discussion of the regulation of gene expression using anti-sense genes, see Weintraub et al., *Reviews-Trends in Genetics*, 1(1) (1986), which is hereby incorporated by reference in its entirety. As
5 discussed *infra*, recombinant molecules including an antisense sequence or oligonucleotide fragment thereof, may be directly introduced into cells of tissues *in vivo* using delivery vehicles such as retroviral vectors, adenoviral vectors and DNA virus vectors. They may also be introduced into cells *in vivo* using physical techniques such as microinjection and electroporation or chemical methods such as coprecipitation and
10 incorporation of DNA into liposomes.

As noted above, the present application allows for the upregulation or downregulation of cell cycle proteins and cell signaling proteins by modifying the BVR levels in cells.

Exemplary cell signaling proteins that can be upregulated by BVR or
15 fragments or variants thereof include, without limitation, creb-2, bfl-1, IAP-1, IAP-2, p16Ink4, beta-casein, p450XIX, GADD45, HIP and RPL13. These and other proteins are shown in Table 1.

Exemplary cell signaling proteins that can be downregulated by BVR or fragments or variants thereof include, without limitation, p27Kip1, p15Ink2b, p18
20 (cdk4 inhibitor), CDX1, FASN and Stra6. These and other proteins are shown in Table 1.

Exemplary cell cycling proteins that can be upregulated by BVR or fragments or variants thereof include, without limitation, cyclins A, E1 and E2, CDK15a, CDC7, cdk1, cdk2, cdk8, Cks2, Cks1p9, Cul1, Cul2, Cul3, E2F-3,
25 MAD2L1, MCM6, Rbx1, and beta-actin. These and other proteins are shown in Table 2.

Exemplary cell cycling proteins that can be downregulated by BVR or fragments or variants thereof include, without limitation, RAD50, cdk4, CDK10, and RPL13A. These and other proteins are shown in Table 2.

30 By virtue of BVR-induced up- or down-regulation of the above-listed cell signaling proteins and cell cycling proteins, it is believed that regulation of BVR levels in cells can thereby modify cell signaling and/or cell cycling events under their control. As a result, it is believed that cellular BVR levels can treat or prevent disease

conditions or disorders that involve one or more of the above-listed proteins. Such disease conditions or disorders are described in the subsequent sections that address the functions and pathways in which the proteins are involved.

5

BAX

Development as well as maintenance of many adult tissues is achieved by several dynamically regulated processes that include cell proliferation, differentiation, and programmed cell death. Oltvai et al., *Cell* 74:609-619 (1993) noted that, in the latter process, cells are eliminated by a highly characteristic suicide
10 program called apoptosis. The best-defined genetic pathway of cell death exists in the nematode *Caenorhabditis elegans*. Two autosomal recessive death effector genes, *ced-3* and *ced-4*, are required for the death of all 131 cells destined to die during worm development. One autosomal dominant death repressor gene, *ced-9*, can save
15 those cells in its gain-of-function form. This implies that both effector and repressor genes also exist within each mammalian cell death pathway. BCL2 is one such mammalian gene that has been identified; it functions as a repressor of programmed cell death.

Oltvai et al., *Cell* 74:609-619 (1993) showed that BCL2 associates in vivo with a 21-kD program partner, Bax. Bax shows extensive amino acid homology
20 with BCL2 and forms homodimers and heterodimers with BCL2 in vivo. When Bax predominates, programmed cell death is accelerated, and the death repressor activity of BCL2 is countered. Their findings suggest a model in which the ratio of BCL2 to Bax determines survival or death following an apoptotic stimulus.

The Bax gene promoter region contains 4 motifs with homology to
25 consensus p53-binding sites. In cotransfection assays using p53-deficient tumor cell lines, Miyashita and Reed, *Cell* 80:293-299 (1995) found that wildtype but not mutant p53 expression plasmids transactivated a reporter gene plasmid that utilized the Bax gene promoter to drive transcription of chloramphenicol acetyltransferase. Introduction of mutations into the consensus p53-binding site sequences abolished
30 p53 responsiveness of the reporter gene plasmids. Taken together, the results suggested that Bax is a primary-response gene for p53 and is involved in a p53-regulated pathway for induction of apoptosis.

Apte et al., *Genomics* 26:592-594 (1995) isolated a Bax cDNA clone in which the mRNA encoded by exon 3 was absent. The skipping of exon 3 predicted the existence of an interstitially truncated form of the major Bax protein (Bax-alpha), termed Bax-delta. Unlike 2 previously described variant forms, Bax-delta retains the functionally critical C-terminal membrane anchor region, as well as the BCL2 homology 1 and 2 (BH1 and BH2) domains.

Carton et al., *Hum. Molec. Genet.* 11:675-687 (2002) examined the expression of Bax in 55 patients with glioblastoma multiforme, the most common and aggressive form of brain tumors. The authors identified a novel form of Bax, designated Bax-psi, which was present in 24% of the patients. Bax-psi is an N-terminal truncated form of Bax which results from a partial deletion of exon 1 of the Bax gene. Bax-psi and the wildtype form, Bax-alpha, are encoded by distinct mRNAs, both of which are present in normal tissues. Glial tumors expressed either Bax-alpha or Bax-psi proteins, an apparent consequence of an exclusive transcription of the corresponding mRNAs. The Bax-psi protein was preferentially localized to mitochondria and was a more powerful inducer of apoptosis than Bax-alpha. Bax-psi tumors exhibited slower proliferation in Swiss nude mice, and this feature could be circumvented by the coexpression of the BCL2 transgene, the functional antagonist of Bax. The expression of Bax-psi correlated with a longer survival in patients (18 months versus 10 months for Bax-alpha patients). The authors hypothesized a beneficial involvement of the psi variant of Bax in tumor progression.

During transduction of an apoptotic signal into the cell, there is an alteration in the permeability of the membranes of the cell's mitochondria, which causes the translocation of the apoptogenic protein cytochrome c into the cytoplasm, which in turn activates death-driving proteolytic proteins known as caspases. The BCL2 family of proteins, whose members may be antiapoptotic or proapoptotic, regulates cell death by controlling this mitochondrial membrane permeability during apoptosis. Shimizu et al., *Nature* 399:483-487 (1999) created liposomes that carried the mitochondrial porin channel VDAC to show that the recombinant proapoptotic proteins Bax and Bak accelerate the opening of VDAC, whereas the antiapoptotic protein BCLXL closes VDAC by binding to it directly. Bax and Bak allow cytochrome c to pass through VDAC out of liposomes, but passage is prevented by BCLXL. In agreement with this, VDAC1-deficient mitochondria from a mutant yeast

did not exhibit a Bax/Bak-induced loss in membrane potential and cytochrome c release, both of which were inhibited by BCLXL. Shimizu et al., *Nature* 399:483-487 (1999) concluded that the BCL2 family of proteins bind to the VDAC in order to regulate the mitochondrial membrane potential and the release of cytochrome c during apoptosis.

To assess the role of Bax in drug-induced apoptosis in human colorectal cancer cells (HCT116 cells), Zhang et al., *Science* 290:989-992 (2000) generated cells that lacked functional Bax genes. Such cells were partially resistant to the apoptotic effects of the chemotherapeutic agent 5-fluorouracil, but apoptosis was not abolished. In contrast, the absence of Bax completely abolished the apoptotic response to the chemopreventive agent sulindac and other nonsteroidal antiinflammatory drugs (NSAIDs). NSAIDs inhibited the expression of the antiapoptotic protein BCLXL, resulting in an altered ratio of Bax to BCLXL and subsequent mitochondria-mediated cell death. Zhang et al. (2000) concluded that their results establish an unambiguous role for Bax in apoptotic processes in human epithelial cancers and may have implications for cancer chemoprevention strategies.

Studies of Bax-deficient mice indicated that the pro-apoptotic Bax molecule can function as a tumor suppressor. For that reason, Meijerink et al., *Blood* 91:2991-2997 (1998) examined human hematopoietic malignancies and found that approximately 21% of lines possessed mutations in Bax, perhaps most commonly in the acute lymphoblastic leukemia subset. Approximately half were nucleotide insertions or deletions within a deoxyguanosine (G8) tract, resulting in a proximal frameshift and loss of immunodetectable Bax protein. Other Bax mutants bore single amino acid substitutions within BH1 or BH3 domains, demonstrated altered patterns of protein dimerization, and had lost death-promoting activity.

The proapoptotic Bax protein induces cell death by acting on the mitochondria. Bax binds to the permeability transition pore complex (PTPC), a composite proteaceous channel that is involved in the regulation of mitochondrial membrane permeability. Marzo et al., *Science* 281:2027-2031 (1998) found that immunodepletion of Bax from PTPC or purification of PTPC from Bax-deficient mice yielded a PTPC that could not permeabilize membranes in response to atractyloside, a proapoptotic ligand of the adenine nucleotide translocator (ANT). Bax and ANT coimmunoprecipitated and interacted in the yeast 2-hybrid system.

Ectopic expression of Bax induced cell death in wildtype but not in ANT-deficient yeast. Recombinant Bax and purified ANT, but neither of them alone, efficiently formed atractyloside-responsive channels in artificial membranes. Hence, the proapoptotic molecule Bax and the constitutive mitochondrial protein ANT cooperate
5 within the PTPC to increase mitochondrial membrane permeability and to trigger cell death.

The caspase-activated form of BID, tBID, triggers the homooligomerization of multidomain conserved proapoptotic family members BAK or Bax, resulting in the release of cytochrome c from mitochondria. Wei et al.,
10 *Science* 292:727-730 (2001) found that cells lacking both BAK and Bax, but not cells lacking only one of these components, are completely resistant to tBID-induced cytochrome c release and apoptosis. Moreover, doubly deficient cells are resistant to multiple apoptotic stimuli that act through disruption of mitochondrial function: staurosporine, ultraviolet radiation, growth factor deprivation, etoposide, and the
15 endoplasmic reticulum stress stimuli thapsigargin and tunicamycin. Thus, Wei et al. (2001) concluded that activation of a 'multidomain' proapoptotic member, BAK or Bax, appears to be an essential gateway to mitochondrial dysfunction required for cell death in response to diverse stimuli.

Polycyclic aromatic hydrocarbons (PAHs) are toxic chemicals released
20 into the environment by fossil fuel combustion. Oocyte destruction and ovarian failure occur in PAH-treated mice, and cigarette smoking causes early menopause in women. In many cells, PAHs activate the aromatic hydrocarbon receptor (AHR), a member of the Per-Arnt-Sim family of transcription factors. The AHR is also activated by dioxin, one of the most intensively studied environmental contaminants.
25 Matikainen *Nature Genet.* 28:355-360 (2001) demonstrated that exposure of mice to PAHs induces the expression of Bax in oocytes, followed by apoptosis. Ovarian damage caused by PAHs is prevented by Ahr or Bax inactivation. Oocytes microinjected with a Bax promoter-reporter construct show Ahr-dependent transcriptional activation after PAH, but not dioxin, treatment, consistent with
30 findings that dioxin is not cytotoxic to oocytes. This difference in the action of PAHs versus dioxin is conveyed by a single basepair flanking each Ahr response element in the Bax promoter. Oocytes in human ovarian biopsies grafted into immunodeficient mice also accumulated Bax and underwent apoptosis after PAH exposure in vivo.

Thus, AHR-driven Bax transcription is a novel and evolutionarily conserved cell-death signaling pathway responsible for environmental toxicant-induced ovarian failure.

To investigate the relationship between apoptosis and the BCL2/Bax system in the human corpus luteum, Sugino et al., *J. Clin. Endocr. Metab.* 85:4379-4386 (2000) examined the frequency of apoptosis and expression of BCL2 and Bax in the corpus luteum during the menstrual cycle and in early pregnancy. Immunohistochemistry revealed BCL2 expression in the luteal cells in the midluteal phase and early pregnancy, but not in the regressing corpus luteum. In contrast, Bax immunostaining was observed in the regressing corpus luteum, but not in the midluteal phase or early pregnancy. The BCL2 mRNA levels in the corpus luteum during the menstrual cycle were highest in the midluteal phase and lowest in the regressing corpus luteum. In the corpus luteum of early pregnancy, BCL2 mRNA levels were significantly higher than those in the midluteal phase. In contrast, Bax mRNA levels were highest in the regressing corpus luteum and remarkably low in the corpus luteum of early pregnancy. When corpora lutea of the midluteal phase were incubated with CG, CG significantly increased the mRNA and protein levels of BCL2 and significantly decreased those of Bax. Sugino et al. (2000) concluded that BCL2 and Bax may play important roles in the regulation of the life span of the human corpus luteum by controlling the rate of apoptosis. CG may act to prolong the life span of the corpus luteum by increasing BCL2 expression and decreasing Bax expression when pregnancy occurs.

LeBlanc et al., *Nature Med.* 8:274-281 (2002) demonstrated that Bax can be essential for death receptor-mediated apoptosis in cancer cells. Bax-deficient human colon carcinoma cells were resistant to death-receptor ligands, whereas Bax-expressing sister clones were sensitive. Bax was dispensable for apical death-receptor signaling events including caspase-8 activation, but crucial for mitochondrial changes and downstream caspase activation. Treatment of colon cancer cells deficient in DNA mismatch repair with the TRAIL selected in vitro or in vivo for refractory subclones with Bax frameshift mutations including deletions at a novel site. Chemotherapeutic agents upregulated expression of the TRAIL receptor DR5 and the Bax homolog BAK in Bax $-/-$ cells, and restored TRAIL sensitivity in vitro and in vivo. Thus, Bax mutation in mismatch repair-deficient tumors can cause resistance to

death receptor-targeted therapy, but pre-exposure to chemotherapy rescues tumor sensitivity.

Guo et al., *Nature* 423:456-461 (2003) found that Bax coimmunoprecipitated with humanin, a peptide with neuroprotective activities against Alzheimer disease-associated insults, and that humanin rescued rat hippocampal neurons from Bax-induced lethality. Humanin prevented the translocation of Bax from the cytosol to the mitochondria and suppressed cytochrome c release. Guo et al. (2003) noted that the predicted humanin peptides from the nuclear-encoded peptide and the mitochondrial-encoded peptide were both able to bind Bax and prevent apoptosis. The authors suggested that the HN gene arose from mitochondria and transferred to the nuclear genome, providing a protective mechanism for additional organelles.

Cancers of the microsatellite mutator phenotype (MMP) show exaggerated genomic instability at simple repeat sequences. The human Bax gene contains a tract of 8 consecutive deoxyguanosines in the third coding exon, spanning codons 38 to 41. To determine whether this sequence is a mutational target in MMP(+) tumor cells, Rampino et al., *Science* 275: 967-969 (1997), amplified by PCR the region containing the (G)8 tract from various MMP(+) tumor cell lines. This analysis revealed band shifts, suggestive of 1-bp insertions and deletions in some of these tumor cells. Homozygous (or hemizygous) frameshift insertion or deletion mutations in Bax were found in multiple primary colorectal cancers as well as colorectal cancer cell lines. The resulting frameshift was thought to interfere with the suppressor role of the wildtype Bax gene. Rampino et al (1997) noted that colon tumors of the MMP type typically do not contain p53 mutations, in contrast with those of the suppressor pathway. Once the MMP is manifested (after the occurrence of mutator mutations in, for example, mismatch repair genes), mutations at the Bax (G)8 hotspot would be more likely to occur than other frameshift or missense mutations in p53. In tumor cells with frameshift Bax mutations, transcriptional activation of Bax by wildtype p53 would be irrelevant. In cancer of the MMP, the generation of thousands of DNA mismatches during every replication of each MMP(+) tumor cell may trigger the p53-mediated apoptotic response to DNA damage. But the response would be futile because the chain leading to apoptosis is broken in a downstream link. Therefore, Rampino et al. (1997) speculated that Bax

mutations eliminate the selective pressure for p53 mutations during colorectal tumorigenesis.

Female mammals are endowed with a finite number of oocytes at birth, each enclosed by a single layer of somatic (granulosa) cells in a primordial follicle.

5 The fate of most follicles is atretic degeneration, a process that culminates in near exhaustion of the oocyte reserve at approximately the fifth decade of life in women, leading to menopause. Apoptosis has a fundamental role in follicular atresia, and several studies had indicated that Bax, which is expressed in both granulosa cells and oocytes, may be central to ovarian cell death. Perez et al., *Nature Genet.* 21:200-203

10 (1999) showed that young adult female mice homozygous for disruption of the Bax gene, (Bax $-/-$), possessed 3-fold more primordial follicles in their ovarian reserve than their wildtype sisters, and that this surfeit of follicles was maintained in advanced chronologic age, such that 20- to 22-month-old female Bax $-/-$ mice possessed hundreds of follicles at all developmental stages and exhibited ovarian steroid-driven

15 uterine hypertrophy. These observations contrasted with the ovarian and uterine atrophy seen in aged wildtype female mice. Aged female Bax $-/-$ mice failed to become pregnant when housed with young adult males; however, metaphase II oocytes could be retrieved from, and corpora lutea formed in, ovaries of aged Bax $-/-$ females following superovulation with exogenous gonadotropins, and some oocytes

20 were competent for in vitro fertilization and early embryogenesis. Therefore, ovarian lifespan could be extended by selectively disrupting Bax function, but other aspects of normal reproductive performance remained defective in aged Bax $-/-$ female mice.

The central nervous system (CNS) of Atm null mice shows a pronounced defect in apoptosis induced by genotoxic stress, suggesting that ATM

25 functions to eliminate neurons with excessive genomic damage. Chong et al., *Proc. Nat. Acad. Sci.* 97: 889-894 (2000) reported that the death effector Bax is required for a large proportion of Atm-dependent apoptosis in the developing CNS after ionizing radiation (IR). Although many of the same regions of the CNS in both Bax $-/-$ and Atm $-/-$ mice were radioresistant, mice nullizygous for both Bax and Atm showed

30 additional reduction in IR-induced apoptosis in the CNS. Therefore, although the major IR-induced apoptotic pathway in the CNS requires Atm and Bax, a p53-dependent collateral pathway exists that has both Atm- and Bax-independent branches. Furthermore, Atm- and Bax-dependent apoptosis in the CNS also required

caspase-3 activation. These data implicated Bax and caspase-3 as death effectors in neurodegenerative pathways.

Proapoptotic Bcl2 family members have been proposed to play a central role in regulating apoptosis, yet mice lacking Bax display limited phenotypic abnormalities. Lindsten et al., *Molec. Cell* 6:1389-1399 (2000) found that Bak $-/-$ mice were developmentally normal and reproductively fit and failed to develop any age-related disorders. However, when Bak-deficient mice were mated to Bax-deficient mice to create mice lacking both genes, the majority of Bax $-/-$ Bak $-/-$ animals died perinatally, with fewer than 10% surviving into adulthood. Bax $-/-$ Bak $-/-$ mice displayed multiple developmental defects, including persistence of interdigital webs, an imperforate vaginal canal, and accumulation of excess cells within both the central nervous and hematopoietic systems. Thus, the authors concluded that Bax and Bak have overlapping roles in the regulation of apoptosis during mammalian development and tissue homeostasis.

Scorrano et al., *Science* 300:135-139 (2003) found that mouse embryonic fibroblasts deficient for Bax and Bak had a reduced resting concentration of calcium in the endoplasmic reticulum (ER) that resulted in decreased uptake of calcium by mitochondria after calcium release from the ER. Expression of SERCA (sarcoplasmic-endoplasmic reticulum calcium adenosine triphosphatase) corrected ER calcium concentration and mitochondrial calcium uptake in double knockout cells, restoring apoptotic death in response to agents that release calcium from intracellular stores, such as arachidonic acid, C2-ceramide, and oxidative stress. In contrast, targeting of Bax to mitochondria selectively restored apoptosis to 'BH3-only' signals. A third set of stimuli, including many intrinsic signals, required both ER-released calcium and the presence of mitochondrial Bax or Bak to fully restore apoptosis. Scorrano et al. (2003) concluded that Bax and BAK operate in both the ER and the mitochondria as an essential gateway for selected apoptotic signals.

Garcia-Barros et al., *Science* 300:1155-1159 (2003) investigated the hypothesis that tumor response to radiation is determined not only by tumor cell type but also by microvascular sensitivity. MCA/129 fibrosarcomas and B16F1 melanomas grown in apoptosis-resistant 'acid sphingomyelinase' (asmase)-deficient or Bax-deficient mice displayed markedly reduced baseline microvascular endothelial apoptosis and grew 200 to 400% faster than tumors on wildtype microvasculature.

Thus, Garcia-Barros et al. (2003) concluded that endothelial apoptosis is a homeostatic factor regulating angiogenesis-dependent tumor growth. Moreover, these tumors exhibited reduced endothelial apoptosis upon irradiation and, unlike tumors in wildtype mice, they were resistant to single-dose radiation up to 20 Gy. Garcia-Barros et al. (2003) concluded that microvascular damage regulates tumor cell response to radiation at the clinically relevant dose range.

Rampino et al., *Science* 275:967-969 (1997) found that more than 50% (21 of 41) of human MMP(+) colon adenocarcinomas they examined had frameshift mutations in a tract of 8 deoxyguanosines within the Bax gene in the third coding exon, spanning codons 38 to 41. These mutations were absent in MMP(-) tumors and were significantly less frequent in G8 tracts from other genes. Frameshift mutations were present in both Bax alleles and some MMP(+) colon tumor cell lines and in primary tumors. These results suggested that inactivating Bax mutations are selected for during the progression of colorectal MMP(+) tumors and that the wildtype Bax gene plays a suppressor role in a p53-independent pathway for colorectal carcinogenesis.

In a patient with T-cell acute lymphoblastic leukemia, Meijerink et al., *Blood* 91:2991-2997 (1998) found a gly67-to-arg missense mutation of the Bax gene.

In several cell lines from patients with T-cell acute lymphoblastic leukemia, Meijerink et al., *Blood* 91:2991-2997 (1998) found deletion of 7 guanine residues from a simple tract of 8 such residues encompassing codons 38 to 41 of the Bax gene.

BFL-1

Programmed cell death (apoptosis) plays an important role in embryonic development, deletion of autoreactive T lymphocytes, and homeostasis. Genes regulating apoptosis include p53, a tumor suppressor gene, MYC, a protooncogene, and BCL2. Lin et al., *J. Immun.* 151:1979-1988 (1993) isolated a novel mouse cDNA sequence, designated BCL2-related protein A1 (Bfl-1) by them, and identified it as a member of the BCL2 family of apoptosis regulators by the predicted protein sequence. Lin et al., *Blood* 87: 983-992 (1996) demonstrated that the A1 protein, although regulated differently from BCL2, has similar antiapoptotic activity.

Choi et al., *Oncogene* 11:1693-1698 (1995) isolated a BCL2-related gene from human fetal liver. Homology to the BH1 and BH2 domains of BCL2 was striking. Bfl-1 is abundantly expressed in bone marrow and at a low level in some other tissues. A correlation was noted between the expression level of Bfl-1 and the development of stomach cancer in 8 sets of clinical samples. Choi et al. (1995) speculated that Bfl-1 is involved in the promotion of cell survival during development or progression of stomach cancer. Choi et al., *Mammalian Genome* 8: 781-782 (1997) showed that Bfl-1 is the human homolog of murine A1.

D'Sa-Eipper et al., *Cancer Res.* 56:3879-3882 (1996) showed that the Bfl-1 protein suppresses apoptosis induced by the p53 tumor suppressor protein in a manner similar to other BCL2 family members. The Bfl-1 gene showed a dominant cooperating oncogenic activity with the E1A oncogene in transformation of primary rodent epithelial cells.

Using mast cells from wildtype and Bfl-1-deficient mice, Xiang et al., *J. Exp. Med.* 194:1561-1569 (2001) showed that knockout mice had normal numbers of mast cells in skin, lung, and spleen. Bone marrow-derived mast cells from normal mice expressed Bfl-1 after activation and, like Bfl-1-deficient mice, released granule mediators. However, mast cells from Bfl-1-deficient mice did not survive allergen activation in vitro, and mast cell number was reduced in vivo after allergen sensitization and provocation. Xiang et al. (2001) proposed that Bfl-1 could be a target in the treatment of allergic diseases.

BETA-CASEIN

The caseins have been shown to be members of a multigene family in at least 2 species, cow and man. They are among the most rapidly diverging groups of proteins. Bovine milk contains 4 caseins, 2 alpha, 1 beta, and 1 kappa. Human milk, on the other hand, contains only 2 caseins, beta and kappa. Beta-casein is the major casein in human milk, accounting for as much as 30% of its total protein mass. In addition to being the primary source of essential amino acids, beta-casein, in concert with kappa-casein, forms micelles that transport calcium and phosphorus to the developing infant. Menon and Ham, *Nucleic Acids Res.* 17:2869 (1989) and Lonnerdal et al., *FEBS Lett.* 269:153-156 (1990) cloned cDNAs for human beta-casein.

Comparison with other species indicates that the caseins are among the most rapidly evolving proteins. Nevertheless, a number of well-conserved residues are distributed along its entire length. These residues are thought to play an important role in conserving the 3-dimensional structure of the protein. Menon et al., *Genomics* 5 12:13-17 (1992) showed that in relation to the beta-casein of other species, the mature protein in the human shows a deletion of amino acids encoded by exon 3. They concluded that an interruption of the polypyrimidine tract adjacent to the 5-prime end of the exon 3 sequence may account for the omission of the exon from human beta-casein mRNA. They stated that a broader sampling would be required for a firm 10 conclusion that exon 3 is never expressed in human beta-casein. Nevertheless, the lack of expression of exon 3 is at the very least a frequent occurrence in humans and may well be species-specific. Exon 3 encodes 9 residues, including 2 additional phosphorylation sites, serine residues 7 and 8. The N-terminal phosphoserine/phosphothreonine amino acids of beta-casein are crucial to the biologic 15 function of the molecule, and variations in their number could affect the overall quality of milk.

GADD45

Ionizing radiation can induce specific genes in mammalian and other 20 eukaryotic cells. Two such genes, often referred to as GADD45 and GADD153, are strongly and coordinately induced by ultraviolet radiation and alkylating agents in human and hamster cells. (These genes are designated GADD for 'growth arrest- and DNA damage-inducible.')

Papathanasiou et al., *Molec. Cell. Biol.* 11:1009-1016 (1991) found that GADD45 but not GADD153 is strongly induced by x-rays in 25 human cells. No induction was seen after treatment with a known activator of protein kinase C. Therefore, GADD45 is the only known x-ray responsive gene whose induction is not mediated by PKC. Sequence analysis of human and hamster cDNA clones demonstrated that the gene has been highly conserved and encodes a novel 165-amino acid polypeptide that is 96% identical in the 2 species. In cell lines from 4 30 patients with ataxia-telangiectasia, Papathanasiou et al. (1991) demonstrated that induction by x-ray of GADD45 mRNA was reduced in comparison to the normal.

The stress-responsive p38 and JNK mitogen-activated protein kinase (MAPK) pathways regulate cell cycle and apoptosis. A human MAP3K, MTK1,

mediates activation of both p38 and JNK in response to environmental stresses. By screening a placenta cDNA library using a yeast 2-hybrid method, Takekawa and Saito, *Cell* 95:521-530 (1998) isolated cDNAs encoding 3 related proteins, GADD45A, GADD45-beta, and GADD45-gamma (GADD45G), that bound to an N-terminal domain of MTK1. GADD45A, GADD45B, and GADD45G share 55 to 58% amino acid identity. These proteins activated MTK1 kinase activity, both in vivo and in vitro. All 3 GADD45-like genes were induced by environmental stresses, including methyl methanesulfonate, UV, and gamma irradiation. Expression of the GADD45-like genes induced p38/JNK activation and apoptosis, which could be partially suppressed by coexpression of a dominant inhibitory MTK1 mutant protein. Northern blot analysis detected moderate expression of a 1.4-kb GADD45A transcript in heart, skeletal muscle, and kidney, with little or no expression in brain, placenta, lung, liver, and pancreas. Takekawa and Saito (1998) proposed that the GADD45-like proteins mediate activation of the p38/JNK pathway, via MTK1, in response to environmental stresses.

CREB-2 (ATF)

An activating transcription factor (ATF)-binding site is a promoter element present in a wide variety of viral and cellular genes, including E1A-inducible adenoviral genes and cAMP-inducible cellular genes. Hai et al., *Genes Dev.* 3:2083-2090 (1989) identified cDNAs encoding 8 different human ATF consensus-binding proteins, including a partial cDNA corresponding to ATF4. They found that members of this family share significant sequence similarity within a leucine zipper DNA-binding motif and an adjacent basic region; the proteins show little similarity outside of these regions.

The cAMP response element (CRE) is an octanucleotide motif that mediates diverse transcriptional regulatory effects. By screening a Jurkat T-cell line expression library for the ability to bind CRE, Karpinski et al., *Proc. Nat. Acad. Sci.* 89:4820-4824 (1992) isolated and characterized a full-length cDNA corresponding to ATF4, which they called CREB2 (CRE-binding protein-2). The predicted protein contains 351-amino acids. Northern blot analysis revealed that the 1.5-kb CREB2 mRNA was expressed in all human tumor cell lines and mouse organs tested. Unlike CREB, which activates transcription from CRE-containing promoters, CREB2

functions as a specific repressor of CRE-dependent transcription. The transcriptional repressor activity resides within the C-terminal leucine zipper and basic domain region of the CREB2 protein.

The p40tax gene product of human T-cell leukemia virus type 1 (HTLV-1) activates HTLV-1 viral transcription in trans through tax-responsive enhancers in the long terminal repeats. Tsujimoto et al., *J. Virol.* 65:1420-1426 (1991) identified ATF4 (CREB2) as TAXREB67, a protein that binds to the tax-responsive enhancer element in HTLV-1.

Tanaka et al., *Genes Cells* 3:801-810 (1998) used gene targeting to generate mice lacking Atf4 (CREB2). They found that Atf4-deficient mice exhibited severe microphthalmia. The Atf4-deficient eyes revealed a normal gross lens structure up to embryonic day 14.5, after which the lens degenerated due to apoptosis without the formation of lens secondary fiber cells. Retinal development was normal in the mutant mice. The lens-specific expression of Atf4 in the mutant mice led not only to the recovery of lens secondary fibers but also to the induction of hyperplasia of these fibers. Tanaka et al. (1998) concluded that ATF4 is essential for the later stages of lens fiber cell differentiation.

ATF-2 as a homodimer or heterodimer bind to cAMP response element, and overexpression of ATF-2 has been shown to significantly enhance growth rate and proliferation of cells grown under stress conditions (Huguier et al., *MCB* 18:7020 (1998), which is hereby incorporated by reference in its entirety) and exposed to DNA damaging radiation (Koolj et al., *Oncogene* 22:4235 (2003), which is hereby incorporated by reference in its entirety). A main protective response of cells to ionizing radiation, UV damage, and DNA damaging factors is induction of cell cycle arrest through the activation of cell cycle check points. This period of quiescence allows the cell to recognize and repair DNA damage. ATF-2 is one of the transcription factors that acts on an essential enzyme in cell cycle arrest, ATM kinase. Because increased BVR expression has been shown to upregulate ATF-2, it is believed that BVR can induce enhanced growth rate and proliferation of cells grown under stress conditions. ATF-2 plays an important role in placenta formation and development of the skeletal as well as the central nervous systems, oncogenic transformation and adaptive response to viral infection and genotoxic stress (Reinhold et al., *Nature* 379:262 (1996); Maekawa et al., *J Biol Chem* 274:17813 (1999); Liu and Green *Cell*

61:1217 (1990); VanDam and Castellazzi, *Oncogene* 202:453 (2001); VanDam et al., *EMBO J* 14:1798 (1995), which are hereby incorporated by reference in their entirety).

IAP-1/IAP-2

5 By testing hybrids containing various deletions of chromosome 3, Miller et al., *Am. J. Hum. Genet.* 41:1061-1070 (1987) described an IgM monoclonal antibody, 1D8, that recognized an antigen coded by a gene located in the region 3cen-q22. The monoclonal antibody was designated MER6. The antigen was absent in the Rh deficiency syndrome, Rh-null hemolytic anemia. This antigen probably had no
10 pathogenetic role in the Rh deficiency, which was shown by Cherif-Zahar et al., *Nature Genet.* 12:168-173 (1996) to be due to mutation in the Rh50 gene on chromosome 6. They noted that many cell membrane components are missing from the multisubunit Rh complex when the RH50A gene is mutant.

Integrin-associated protein (IAP) is a 50-kD membrane protein with an
15 amino-terminal immunoglobulin domain and a carboxyl-terminal multiple-membrane-spanning region. It is involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to extracellular matrix. IAP is also expressed on erythrocytes, which have no known integrins. IAP is identical to OA3, an ovarian carcinoma antigen (Mawby et al., *Biochem. J.* 304:525-530 (1994)). Lindberg et al.,
20 *J. Biol. Chem.* 269:1567-1570 (1994) showed that IAP expression is reduced on Rh(null) erythrocytes. By fluorescence in situ hybridization they showed that the IAP structural gene maps to 3q13.1-q13.2, within a region known to contain a gene encoding the Rh-associated 1D8 antigen. By expression studies on human erythrocytes and IAP transfectants, IAP was shown to be identical to the 1D8 antigen
25 and to CD47, a cell surface protein with broad tissue distribution, reduced in expression on Rh(null) erythrocytes. Lindberg et al. (1994) stated that these studies demonstrated an unexpected link between integrin signal transduction and erythrocyte membrane structure.

P16(INK4)

30 Cyclin-dependent kinase inhibitor-2A (CDKN2A) goes by the colloquial designation p16, which is sometimes referred to as p16(INK4). The gene was originally symbolized MTS1 (for multiple tumor suppressor-1) by Kamb et al.,

Science 264: 436-440 (1994), who later used the symbol CDKN2 because MTS1 had been preempted by the malignant transformation suppression-1 gene located on 1p.

Chromosome region 9p21 is involved in chromosomal inversions, translocations, heterozygous deletions, and homozygous deletions in a variety of malignant cell lines including those from glioma, nonsmall cell lung cancer, leukemia, and melanoma. Deletion of 9p21 markers is found in more than half of all melanoma cell lines. These findings suggest that 9p21 contains a tumor suppressor locus that may be involved in the genesis of several tumor types. Kamb et al., *Science* 264:436-440 (1994) localized a putative tumor suppressor locus to band 9p21 in a region of less than 40 kb by means of analyzing homozygous deletions in melanoma cell lines. The region was found to contain a gene, called MTS1 (for multiple tumor suppressor-1), that encodes a previously identified inhibitor (p16) of cyclin-dependent kinase-4 (CDK4). The sequence of the MTS1 gene as determined by Kamb et al. (1994) was identical to that of the p16 gene as determined by Serrano et al., *Nature* 366:704-707 (1993). MTS1 was found to be homozygously deleted at high frequency in cell lines derived from tumors of lung, breast, brain, bone, skin, bladder, kidney, ovary, and lymphocyte. Melanoma cell lines carried at least one copy of MTS1 in combination with a deleted allele. Melanoma cell lines that carried at least 1 copy of MTS1 frequently showed nonsense, missense, or frameshift mutations in the gene. Thus, MTS1 may rival p53 in the universality of its involvement in tumorigenesis. Furthermore, it illustrates, as does p53, the relationship between the tumor suppressor genes and the regulation of the cell cycle.

The p16 gene (CDKN2A) was mapped to 9p21(Kamb et al. (1994); Nobori et al., *Nature* 368:753-756 (1994)). This same region has frequently been involved in deletions and rearrangements in dysplastic nevi (Cowen et al., *J. Nat. Cancer Inst.* 80: 1159-1164 (1988)), a major precursor lesion of melanoma, and in cutaneous malignant melanoma, or CMM (Fountain et al., *Proc. Nat. Acad. Sci.* 89:10557-10561 (1992)), and was shown by Petty et al., *Am. J. Hum. Genet.* 53:96-104 (1993) to be involved in a constitutional deletion in a patient with multiple primary melanomas. A gene for familial malignant melanoma, symbolized CMM2, has been mapped to 9p21.

The frequent deletion or mutation of CDKN2A in tumor cells suggests that p16 acts as a tumor suppressor. Lukas et al., *Nature* 375:503-506 (1995) showed

that wildtype p16 arrests normal diploid cells in late G1, whereas a tumor-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell cycle arrest was lost in cells lacking functional retinoblastoma protein. Thus, loss of p16, overexpression of D-cyclins, and loss of retinoblastoma have similar effects on G1 progression, and may represent a common pathway to tumorigenesis. The mutation used by Lukas et al. (1995) in their studies was a C-to-T transition changing proline-114 to leucine and had been observed in 3 independent melanoma cell lines. Koh et al., *Nature* 375:506-510 (1995) reported similar results. They demonstrated that p16 can act as a potent and specific inhibitor of progression through the G1 phase of the cell cycle and that several tumor-derived alleles of p16 encode functionally compromised proteins. In vivo, the presence of functional retinoblastoma protein appeared to be necessary but may not be sufficient to confer full sensitivity to p16-mediated growth arrest. In addition to the P114L allele, they used an asp74-to-asn (D74N) mutant, a de novo somatic mutation isolated independently from tumors of the esophagus and bladder; an asp84-to-asn (D84N) mutation found in a survey of esophageal squamous cell carcinomas; and several other mutations associated with melanoma.

Stott et al., *EMBO J.* 17:5001-5014 (1998) stated that the alpha transcript of CDKN2A has been shown to encode p16(INK4a), a recognized tumor suppressor that induces a G1 cell cycle arrest by inhibiting the phosphorylation of the Rb protein by the cyclin-dependent kinases CDK4 and CDK6. The beta transcript of CDKN2A encodes p14(ARF). The predicted 132-amino acid p14(ARF) is shorter than the corresponding mouse protein, p19(ARF), and the 2 proteins share only 50% identity. However, both proteins have the ability to elicit a p53 response, manifest in the increased expression of both CDKN1A and MDM2, and resulting in a distinctive cell cycle arrest in both the G1 and G2/M phases. Zhange et al., *Cell* 92: 25-734 (1998) stated that the 2 unrelated proteins encoded by the INK4A-ARF locus function in tumor suppression. Zhange et al. (1998) showed that ARF binds to MDM2 and promotes the rapid degradation of MDM2. This interaction is mediated by the E1-beta-encoded N-terminal domain of ARF and a C-terminal region of MDM2. ARF-promoted MDM2 degradation is associated with MDM2 modification and concurrent p53 stabilization and accumulation. The functional consequence of ARF-regulated p53 levels via MDM2 proteolysis is evidenced by the ability of ectopically expressed

ARF to restore a p53-imposed G1 cell cycle arrest that is otherwise abrogated by MDM2. Thus, Zhang et al. (1998) concluded that deletion of the ARF-INK4A locus simultaneously impairs the INK4A--cyclin D/CDK4--RB and the ARF--MDM2--p53 pathways.

5 Igaka et al., *Biochem. Biophys. Res. Commun.* 203:1090-1095 (1994) found homozygous deletion of p16 in 12 of 13 esophageal cancer cell lines and in 2 of 9 gastric cancer cell lines. They also found that p16 gene loss, cyclin D1, and p53 gene mutations occurred independently in these cell lines. They interpreted these results as indicating that changes in the p16 gene are involved in most esophageal
10 cancers and play a critical role in the development of this type of malignancy.

Liu et al., *Oncogene* 11:405-412 (1995) described a family with inherited melanoma in which a novel mutation in exon 2 of the p16(INK4A) gene segregated with disease. The mutant allele encoded a protein with an in-frame deletion of 2 amino acids (asp96 and leu97). They showed that the mutant protein is
15 functionally abnormal: it was unable to bind CDK4 in vitro and did not inhibit colony formation in tertiary passage rat embryo fibroblasts. Moreover, in a metastatic lesion from 1 patient, the wildtype allele was deleted and the mutant allele retained. Liu et al. (1995) concluded that family members carrying the germline mutation in this gene are predisposed to melanoma.

20 Pilon et al., *J. Clin. Endocr. Metab.* 84:2776-2779 (1999) investigated inactivation of the p16 tumor suppressor gene in a series of 14 adrenocortical tumors. Using 11 polymorphic microsatellite markers spanning the short arm of chromosome 9, they demonstrated that 3 of 7 adrenocortical carcinomas and 1 of 7 adrenocortical adenomas had LOH within chromosome 9p21, the region containing p16.
25 Immunohistochemistry showed the absence of p16 nuclear staining in all adrenocortical tumors with LOH within 9p21, and positive staining in all remaining tumors without LOH. The authors concluded that LOH within 9p21 associated with lack of p16 expression occurs in a considerable proportion of adrenocortical malignant tumors but is rare in adenomas. Furthermore, they suggested that
30 inactivation of p16 may contribute to the deregulation of cell proliferation in this neoplastic disease.

The p16(INK4A) cyclin-dependent kinase inhibitor is implicated in replicative senescence, the state of permanent growth arrest provoked by cumulative

cell divisions or as a response to constitutive Ras-Raf-MEK signaling in somatic cells. Ohtani et al., *Nature* 409:1067-1070 (2001) demonstrated a role for the ETS1 and ETS2 transcription factors in regulating the expression of p16(INK4A) in these different contexts based on their ability to activate the p16(INK4A) promoter through
5 an ETS binding site and their patterns of expression during the lifespan of human diploid fibroblasts. The induction of p16(INK4A) by ETS2, which is abundant in young human diploid fibroblasts, is potentiated by signaling through the Ras-Raf-MEK kinase cascade and inhibited by a direct interaction with the helix-loop-helix protein ID1. In senescent cells, where the ETS2 levels and MEK signaling decline,
10 the marked increase in p16(INK4A) expression is consistent with the reciprocal reduction of ID1 and accumulation of ETS1.

P27(KIP1)

Stegmaier et al., *Blood* 86:38-44 (1995) studied loss of heterozygosity
15 (LOH) in the region 12p13-p12 in acute lymphoblastic leukemia (this chromosomal region often shows deletion in such patients). In 15% of informative patients, there was evidence of LOH of the TEL locus which was not evident on cytogenetic analysis. Detailed examination of patients with LOH showed that the critically deleted region included a second candidate tumor suppressor gene, referred to by
20 them as KIP1, which encodes the cyclin-dependent kinase inhibitor previously called p27 (Toyoshima and Hunter, *Cell* 78:67-74 (1994) and Polyak et al., *Cell* 78:59-66 (1994)). Based on the STS content of TEL-positive YACs, Stegmaier et al. (1995) reported that KIP1 and TEL were in close proximity.

Cyclin-dependent kinase (CDK, e.g., CDK2) activation requires
25 association with cyclins (e.g., CCNE1) and phosphorylation by CAK (CCNH), and leads to cell proliferation. Inhibition of cellular proliferation occurs upon association of CDK inhibitor (e.g., CDKN1B) with a cyclin-CDK complex. Sheaff et al., *Genes Dev.* 11:1464-1478 (1997) showed that expression of CCNE1-CDK2 at physiologic levels of ATP results in phosphorylation of CDKN1B at thr187, leading to
30 elimination of CDKN1B from the cell and progression of the cell cycle from G1 to S phase. At low ATP levels, the inhibitory functions of CDKN1B are enhanced, thereby arresting cell proliferation.

Apoptosis of human endothelial cells after growth factor deprivation is associated with rapid and dramatic upregulation of cyclin A-associated CDK2 activity. Levkau et al., *Molec. Cell* 1:553-563 (1998) showed that in apoptotic cells the carboxyl-termini of the CDK inhibitors CDKN1A and CDKN1B are truncated by specific cleavage. The enzyme involved in this cleavage is CASP3 and/or a CASP3-like caspase. After cleavage, CDKN1A loses its nuclear localization sequence and exits the nucleus. Cleavage of CDKN1A and CDKN1B resulted in a substantial reduction in their association with nuclear cyclin-CDK2 complexes, leading to a dramatic induction of CDK2 activity. Dominant-negative CDK2, as well as a mutant CDKN1A resistant to caspase cleavage, partially suppressed apoptosis. These data suggested that CDK2 activation, through caspase-mediated cleavage of CDK inhibitors, may be instrumental in the execution of apoptosis following caspase activation.

High levels of p27(KIP1), present in quiescent (G0) cells, have been shown to decline upon mitogen induction (Sherr and Roberts, *Genes Dev.* 9: 1149-1163 (1995)). Braun-Dullaeus, *J. Clin. Invest.* 104:815-823 (1999) explored the role of p27(KIP1) and other cell cycle proteins in mediating angiotensin II-induced vascular smooth muscle cell hypertrophy or hyperplasia. Angiotensin II treatment (100 nM) of quiescent vascular smooth muscle cells led to upregulation of the cell cycle regulatory proteins cyclin D1, CDK2, proliferating cell nuclear antigen, and CDK1. Levels of p27(KIP1), however, remained high, and the activation of the G1-phase CDK2 was inhibited as the cells underwent hypertrophy. Angiotensin II stimulated an increase in [(3)H]thymidine incorporation and the percentage of S-phase cells in p27(KIP1) antisense oligodeoxynucleotide (ODN)-transfected cells but not in control ODN transfected cells. The authors concluded that angiotensin II stimulation of quiescent cells in which p27(KIP1) levels are high results in hypertrophy but promotes hyperplasia when levels of p27(KIP1) are low, as in the presence of other growth factors.

Medema et al., *Nature* 404:782-787 (2000) demonstrated that p27(KIP1) is a major target of AFX-like forkhead proteins. They demonstrated that AFX integrates signals from PI3K/PKB signaling and RAS/RAL signaling to regulate transcription of p27(KIP1). They demonstrated that p27^{-/-} cells are significantly less inhibited by AFX activity than their p27^{+/+} counterparts.

Peters and Ostrander, *Nature Genet.* 27:134-135 (2001) commented on the work of Di Cristofano et al., *Nature Genet.* 27:222-224 (2001), demonstrating how cooperation between Cdkn1b and Pten contribute to suppression of prostate tumors. They gave a useful tabulation of the cytogenetic location of 16 mapped prostate cancer susceptibility loci and candidate genes.

Phosphorylation leads to the ubiquitination and degradation of CDKN1B. Carrano et al., *Nature Cell Biol.* 1: 193-199 (1999) determined that SKP2 specifically recognizes phosphorylated CDKN1B predominantly in S phase rather than in G1 phase, and is the ubiquitin-protein ligase necessary for CDKN1B ubiquitination.

Shin et al., *Nature Med.* 8:1145-1152 (2000) demonstrated a novel mechanism of AKT-mediated regulation of p27(KIP1). Blockade of HER2/NEU in tumor cells inhibited AKT kinase activity and upregulated nuclear levels of p27(KIP1). Recombinant AKT and AKT precipitated from tumor cells phosphorylated wildtype p27 in vitro. P27 contains an AKT consensus RXRXXT(157)D within its nuclear localization motif. Active (myristoylated) AKT phosphorylated wildtype p27 in vivo but was unable to phosphorylate a T157A-p27 mutant. Wildtype p27 localized in the cytosol and nucleus, whereas the mutant p27 localized exclusively in the nucleus and was resistant to nuclear exclusion by AKT. Expression of phosphorylated AKT in primary human breast cancers statistically correlated with the expression of p27 in tumor cytosol. Shin et al. (2002) concluded that AKT may contribute to tumor cell proliferation by phosphorylation and cytosolic retention of p27, thus relieving CDK2 from p27-induced inhibition.

Liang et al., *Nature Med.* 8:1153-1160 (2002) demonstrated that AKT phosphorylates p27, impairs the nuclear import of p27, and opposes cytokine-mediated G1 arrest. In cells transfected with constitutively active AKT, wildtype p27 mislocalized to the cytoplasm, but mutant p27 was nuclear. In cells with activated AKT, wildtype p27 failed to cause G1 arrest, while the antiproliferative effect of the mutant p27 was not impaired. Cytoplasm p27 was seen in 41% (52 of 128) primary human breast cancers in conjunction with AKT activation and was correlated with a poor patient prognosis. Liang et al. (2002) concluded that their data showed a novel mechanism whereby AKT impairs p27 function that is associated with an aggressive phenotype in human breast cancer.

Viglietto et al., *Nature Med.* 8:1136-1144 (2002) independently demonstrated that AKT regulates cell proliferation in breast cancer cells by preventing p27(KIP1)-mediated growth arrest. They also showed that threonine at position 157 is an AKT phosphorylation site and causes retention of p27(KIP1) in the cytoplasm, precluding p27(KIP1)-induced G1 arrest.

Fero et al., *Cell* 85:733-744 (1996) found that targeted disruption of the murine p27(Kip1) gene caused a gene dose-dependent increase in animal size without other gross morphologic abnormalities. All tissues were enlarged and contained more cells, although endocrine abnormalities were not evident. Thymic hyperplasia was associated with increased T-lymphocyte proliferation, and T cells showed enhanced IL2 responsiveness in vitro. Thus, p27 deficiency may cause a cell-autonomous defect resulting in enhanced proliferation in response to mitogens. In the spleen, the absence of p27 selectively enhanced proliferation of hematopoietic progenitor cells. That p27 and Rb function in the same regulatory pathway was suggested by the finding that p27 deletion, like deletion of the Rb gene, uniquely caused neoplastic growth of the pituitary pars intermedia. The absence of p27 also caused an ovulatory defect and female sterility. Maturation of second ovarian follicles into corpora lutea, which express high levels of p27, was markedly impaired.

Zindy et al., *Proc. Nat. Acad. Sci.* 96:13462-13467 (1999) generated mice with targeted deletions of both the Ink4d and Kip1 genes. They found that terminally differentiated, postmitotic neurons in these mice reentered the cell cycle, divided, and underwent apoptosis. Zindy et al. (1999) noted that when either Ink4d or Kip1 alone are deleted, the postmitotic state is maintained, suggesting a redundant role for these genes in mature neurons.

Mitsuhashi et al., *Proc. Nat. Acad. Sci.* 98:6435-6440 (2001) described a mouse model in which p27(Kip1) transgene expression was spatially restricted to the central nervous system neuroepithelium and temporally controlled with doxycycline. Transgene-specific transcripts were detectable within 6 hours of doxycycline administration, and maximum nonlethal expression was approached within 12 hours. After 18 to 26 hours of transgene expression, the G1 phase of the cell cycle was estimated to increase from 9 to 13 hours in the neocortical neuroepithelium, the maximum G1 phase length attainable in this proliferative population in normal mice. Thus, the data established a direct link between

p27(Kip1) and control of G1 phase length in the mammalian central nervous system and unveiled intrinsic mechanisms that constrain the G1 phase length to a putative physiologic maximum despite ongoing p27(Kip1) transgene expression.

Phosphorylation of p27(Kip1) on threonine-187 by CDK2 is thought to initiate the major pathway for p27 proteolysis. To critically test the importance of this pathway in vivo, Malek et al., *Nature* 413: 323-327 (2001) replaced the murine p27 gene with one that encoded alanine instead of threonine at position 187. Malek et al. (2001) demonstrated that cells expressing p27 with the T187A change were unable to downregulate p27 during the S and G2 phases of the cell cycle, but that this had a surprisingly modest effect on cell proliferation both in vitro and in vivo. Malek et al. (2001) demonstrated a second proteolytic pathway for controlling p27, one that is activated by mitogens and degrades p27 exclusively during G1.

P18 (CDK4 Inhibitor)

Cyclin-dependent kinase inhibitors (CKIs) are a group of low molecular weight proteins that associate with cyclin-CDK complexes or CDKs alone and inhibit their activity. Members of the INK4 family of CKIs, which includes CDKN2C, specifically bind and inhibit CDK4 and CDK6, thereby preventing cyclin D-dependent phosphorylation of RB1.

By using a yeast 2-hybrid screen to search for CDK6-interacting proteins, Guan et al., *Genes Dev.* 8:2939-2952 (1994) isolated a partial cDNA encoding a protein that they designated p18 based on its molecular mass of 18 kD. They used the partial cDNA to screen a HeLa cell library and recovered additional cDNAs corresponding to the entire p18 coding region. Sequence analysis revealed that the predicted 168-amino acid p18 protein shares 38% and 42% sequence identity with p16/INK4A and p14/INK4B, respectively. Like p14 and p16, p18 contains an ankyrin repeat domain. Using Northern blot analysis, Guan et al. (1994) found that p18 is expressed as multiple transcripts in various human tissues, with the strongest expression in skeletal muscle.

Guan et al., *Genes Dev.* 8:2939-2952 (1994) showed that, both in vivo and in vitro, p18 interacted strongly with CDK6 and weakly with CDK4, but not with the other CDKs tested. Recombinant p18 inhibited the kinase activity of cyclin D-CDK6 in vitro. Ectopic expression of either p16 or p18 suppressed the growth of

human cells in a manner that appears to correlate with the presence of a wildtype RB1 function.

By fluorescence in situ hybridization, Guan et al. (1994) mapped the p18 gene to 1p32, a chromosomal region associated with abnormalities in a variety of human tumors.

Lapointe et al., *Cancer Res.* 56:4586-4589 (1996) identified a single amino acid substitution (ala72 to pro; A72P) in BT-20 human breast cancer cells that abrogated the ability of p18 to interact with CDK6 and to suppress cell growth. These authors suggested that p18 inactivation by point mutations may contribute to deregulated growth control in certain cell lines and/or tumors. Blais et al., *Biochem. Biophys. Res. Commun.* 247:146-153 (1998) found this p18 variant in 3 of 35 breast tumors examined, and suggested that it may be a polymorphism.

Bai et al., *Molec. Cell. Biol.* 23:1269-1277 (2003) noted that targeted disruption of Ink4c in mice leads to spontaneous pituitary tumors and lymphomas later in life. Treatment of Ink4c null and heterozygous mice with a chemical carcinogen resulted in tumor development at an accelerated rate. Bai et al. (2003) concluded that, since the remaining wildtype allele of Ink4c was neither mutated nor silenced in tumors derived from heterozygotes, Ink4c is a haploinsufficient tumor suppressor in mice.

FASN

Fatty acid synthase ("FASN") catalyzes the conversion of acetyl-CoA and malonyl-CoA, in the presence of NADPH, into long-chain saturated fatty acids (Wakil, *Biochemistry* 28:4523-4530 (1989). In prokaryotes and plants, FASN consists of an acyl carrier protein and 7 structurally independent monofunctional enzymes. In animals, however, all of the component enzymatic activities of FASN and acyl carrier protein are organized in one large polypeptide chain.

Jayakumar et al., *Proc. Nat. Acad. Sci.* 92:8695-8699 (1995) isolated and sequenced cDNA clones representing the 2 ends of the human FASN gene and also isolated overlapping genomic clones from human YAC libraries. By fluorescence in situ hybridization, they mapped the FASN gene to 17q25. Southern analyses suggested that a single 40-kb cosmid clone encompasses the entire coding region of the gene.

Jayakumar et al., *Genomics* 23: 420-424 (1994) purified fatty acid synthase to near homogeneity from a human hepatoma cell line, HepG2. The specific activity of the enzyme was found to be half that of chicken liver enzyme. They also cloned the human brain FASN cDNA. The cDNA sequence had an open reading frame of 7,512 bp that encoded a 2504-amino acid protein with relative mass of 272,516. The amino acid sequence of the human enzyme had 79% and 63% identity, respectively, with the sequences of the rat and chicken enzymes. Northern analysis revealed that human FASN mRNA is about 9.3 kb in size and that its level varies among human tissues, with brain, lung, and liver tissues showing prominent expression. Sequence variants of unknown origin and significance were found in the enzyme derived from HepG2.

Ye et al., *Biochim. Biophys. Acta* 1493:373-377 (2000) investigated the expression of ESR1 in prostate cancer cell lines and unexpectedly found a FASN/ESR1 fusion transcript. Using semi-nested RT-PCR analysis of ESR1 and its variants, Ye et al., (2000) found that the N-terminal coding region of FASN containing domain 1 was fused to the C-terminal coding region of the ESR1 ligand binding domain. Nested RT-PCR also detected the fusion transcript in breast, cervical, and bladder cancer cell lines.

Loftus et al., *Science* 288:2379-2381 (2000) identified a link between anabolic energy metabolism and appetite control. Both systemic and intracerebroventricular treatment of mice with fatty acid synthase inhibitors (cerulenin and C75, a synthetic compound) led to inhibition of feeding and dramatic weight loss. C75 inhibited expression of the prophagic signal neuropeptide Y in the hypothalamus and acted in a leptin-independent manner that appears to be mediated by malonyl-CoA. Loftus et al. (2000) suggested that FASN may represent an important link in feeding regulation and may be a potential therapeutic target for obesity.

In animals, including humans, the source of long chain saturated fatty acids is either de novo synthesis, which is mediated by fatty acid synthase, ingested food, or both. To understand the importance of de novo fatty acid synthesis, Chirala et al., *Proc. Nat. Acad. Sci.* 100:6358-6363 (2003) generated FASN knockout mice. The heterozygous mutant mice were ostensibly normal; however, levels of FASN mRNA and activity were approximately 50% and 35% lower, respectively, than those of wildtype mice. When the heterozygous mutant mice were interbred, no null mice were produced; thus, FASN is essential during embryonic development. Furthermore, the

number of heterozygous progeny was 70% less than predicted by Mendelian inheritance, indicating partial haploid insufficiency. Even when 1 parent was wildtype and the other heterozygous, the estimated loss of heterozygous progeny was 60%. Most of the FASN-null embryos died before implantation and the heterozygous embryos died at various stages of development. Feeding the breeders a diet rich in saturated fatty acids did not prevent the loss of homo- or heterozygotes.

CYCLIN A

Wang et al., *Nature* 343:555-557 (1990) cloned a single hepatitis B virus integration site in a human hepatocellular carcinoma at an early stage of development, and also cloned its germline counterpart. The normal locus was found to be transcribed into 2 polyadenylated mRNA species of 1.8 and 2.7 kb. Wang et al. (1990) isolated a cDNA clone from a normal adult human liver that had an open reading frame with a coding capacity for a protein of 432 amino acids and relative molecular mass of 48,536. Strong homologies in amino acid sequence identified the protein as a human cyclin A. The HBV integration was found to have occurred within an intron. Wang et al. (1990) suggested that disruption of the cyclin A gene by viral insertion was responsible for tumorigenesis.

Cyclins are highly conserved proteins associated with proliferating cells. They show a steady accumulation throughout interphase until the G2/M transition, followed by rapid disappearance at the onset of anaphase. They are highly conserved in evolution, having been identified in yeast, clam, starfish, sea urchin, and *Drosophila*. Two groups of cyclins, A and B, are distinguished on the basis of their sequence and pattern of accumulation during the cell cycle. Both cyclins will complex with and activate the serine-threonine kinase p34(cdc2) during the G2/M phase transition. Cyclins are also referred to as proliferating cell nuclear antigens. Nonrandom integration of HBV in hepatocellular carcinoma has been related to chromosome 11 and to chromosome 4. Furthermore, interruption of the coding region of the gene for retinoic acid receptor beta by viral DNA has been reported. Blanquet et al., *Genomics* 8:595-597 (1990) mapped the CCNA gene to 4q26-q27. They pointed to the interest of this finding in connection with the demonstrated loss of heterozygosity for markers on 4q in tumor tissue of patients with liver cancer (Buetow et al., *Proc. Nat. Acad. Sci.* 86: 8852-8856 (1989).

Girard et al., *Cell* 67:1169-1179 (1991) showed that cyclin A protein is synthesized and localized into the nucleus at the onset of S phase in nontransformed mammalian fibroblasts. Inhibition of cyclin A synthesis or activity through microinjection of plasmids encoding antisense cyclin A cDNA or affinity-purified anti-cyclin A antibodies during G1 phase abolished the nuclear staining for cyclin A and inhibited DNA synthesis. No similar effect was observed with injection of other antisense vectors, including antisense cyclin B. Girard et al. (1991) suggested that cyclin A plays a major role in the control of DNA replication. Henglin et al., *Proc. Nat. Acad. Sci.* 91:5490-5494 (1994) cloned and sequenced the human CCNA gene and cDNAs representing its mRNAs and characterized its promoter. Using synchronized cultures of NIH 3T3 cells stably transfected with cyclin A promoter/luciferase constructs, they showed that the promoter is repressed during the G1 phase of the cell cycle and is activated at S-phase entry. Cell cycle regulation of the CCNA promoter is mediated by sequences extending from -79 to +100 relative to the predominant transcription start site. The presence of a functional retinoblastoma protein is not required.

The mammalian A-type cyclin family consists of 2 members, cyclin A1 and cyclin A2. Cyclin A2 promotes both G1/S and G2/M transitions (Pagano et al., *EMBO J.* 11:961-971 (1992). Murphy et al., *Nature Genet.* 15:83-86 (1997) demonstrated that a targeted deletion of the murine *Ccna2* gene is embryonically lethal, although homozygous null mutant embryos developed normally until postimplantation, approximately day 5.5 postcoitum. The authors suggested that the embryos survived either because a maternal pool of cyclin A2 protein persists until at least the blastocyst stage, or because cyclin A1 plays an unexpected role during early embryo development. Cyclin A1 is expressed in mice exclusively in the germline lineage (Sweeney et al., *Development* 122: 53-64 (1996) and is expressed in humans at highest levels in the testis and certain myeloid leukemia cells (Yang et al., *Cancer Res.* 57: 913-920 (1997)).

CYCLIN E1

Koff et al., *Cell* 66:1217-1228 (1991) isolated a new human cyclin, named cyclin E, by complementation of a triple *cln* deletion in *Saccharomyces cerevisiae*. Cyclin E showed genetic interactions with the CDK18 gene, suggesting that it functions at START by interacting with the CDK18 protein. Two human genes were

identified that could interact with cyclin E to perform START in yeast containing a *cdc28* mutation. One was CDK1-HS, and the second was the human homolog of *Xenopus* CDK2. Keyomarsi et al., *Cancer Res.* 54:380-385 (1994) demonstrated that breast cancers, as well as some other solid tumors, show severe quantitative and qualitative alterations in cyclin E protein production. In breast cancer, the alterations in cyclin E expression became progressively worse with increasing stage and grade of the tumor, suggesting its potential use as a prognostic marker.

Cyclin-dependent kinase (CDK) activation requires association with cyclins (e.g., Cyclin E1) and phosphorylation by CAK, and leads to cell proliferation. Inhibition of cellular proliferation occurs upon association of CDK inhibitor (e.g., CDKN1B) with a cyclin-CDK complex. Sheaff et al., *Genes Dev.* 11:1464-1478 (1997) showed that expression of Cyclin E1-CDK2 at physiologic levels of ATP results in phosphorylation of CDKN1B at thr187, leading to elimination of CDKN1B from the cell and progression of the cell cycle from G1 to S phase. At low ATP levels, the inhibitory functions of CDKN1B are enhanced, thereby arresting cell proliferation.

Keyomarsi et al., *New Eng. J. Med.* 347:1566-1575 (2002) investigated cyclin E as a determinant of the virulence and metastatic potential of breast cancer cells. In normal dividing cells, cyclin E regulates the transition from the G1 phase to the S phase, and a high level of cyclin E protein accelerates the transition through the G1 phase. They assayed for cyclin E in tumor tissue from 395 patients with breast cancer and correlated the findings with follow-up (median 6.4 years). Levels of total cyclin E and low-molecular weight cyclin E in tumor tissue, as measured by Western blot assay, correlated strongly with survival in patients with breast cancer. The hazard ratio for death from breast cancer for patients with high total cyclin E levels as compared with those with low total cyclin E levels was 13.3, or about 8 times as high as the hazard ratios associated with other independent clinical and pathologic risk factors.

Cyclins bind to and activate cyclin-dependent kinases (CDKs) to form serine/threonine kinase holoenzyme complexes that regulate the eukaryotic cell cycle. Cyclins A, D and E are required for mammalian cells to traverse G1 and enter S phase. Cyclin E controls the initiation of DNA synthesis by activating CDK2; the KIP1 and CIP1 proteins bind and inhibit cyclin E-CDK2 complexes. By searching an EST database with a cyclin box consensus sequence, Gudas et al., *Molec. Cell. Biol.* 19:612-622 (1999) identified rat and mouse cDNAs encoding cyclin E2. They carried out

additional EST database searches and performed RACE to identify human cyclin E2 cDNAs. Northern blot analysis revealed that the 2.8-kb cyclin E2 mRNA is expressed in several normal human tissues, with the highest levels in testis, thymus, and brain. The level of cyclin E2 transcript was consistently elevated in tumor-derived cells compared to nontransformed proliferating cells. Like cyclin E1, the human cyclin E2 gene complemented a G1 cyclin defect in *S. cerevisiae*. Sequence analysis indicated that the predicted 404-amino acid cyclin E2 protein contains a cyclin box motif and is 47% identical to cyclin E1 (CCNE1).

When expressed in mammalian cells, epitope-tagged cyclin E2 protein localized to the nucleus. The expressed protein associated with CDK2 in a functional kinase complex that was inhibited by both KIP1 and CIP1. Gudas et al. (1999) demonstrated that the catalytic activity associated with cyclin E2 complexes is cell cycle-regulated and peaks at the G1/S transition. Overexpression of either cyclin E1 or cyclin E2 in mammalian cells accelerated G1, indicating that, like cyclin E1, cyclin E2 may be rate-limiting for G1 progression. These authors concluded that multiple unique cyclin E-CDK complexes may regulate cell cycle progression. The researchers also isolated an alternatively spliced human cDNA encoded cyclin E2(SV), a protein missing 45 amino acids within the cyclin box domain. RNase protection assays confirmed that the cyclin E2(SV) mRNA is expressed in normal human thymus. The shorter cyclin E2(SV) isoform did not bind CDK2.

CDK15A

The human CDK15 tyrosine phosphatases trigger activation of CDK1 by removing inhibitory phosphate from tyrosine and threonine residues of the cyclin-dependent kinases. Thus, the genes encoding these phosphatases are suspected of being potential oncogenes because of their role in promoting cell division. Three human CDK15 genes have been identified: CDK15A, CDK15B, and CDK15C. Demetrick and Beach, *Genomics* 18:144-147 (1993) mapped the CDK15A gene to 3p21 by fluorescence in situ hybridization with confirmation by PCR analysis of hamster/human somatic cell hybrid DNAs. An area near 3p21 is frequently involved in karyotypic abnormalities in renal carcinomas, small cell carcinomas of the lung, and benign tumors of the salivary gland.

Galaktionov et al., *Science* 269:1575-1577 (1995) showed that in rodent cells, human CDK15A or CDK15B but not CDK15C phosphatases cooperate with either the gly12-to-val mutation of the HRAS gene or loss of RB1 in oncogenic focus formation. The transformants were highly aneuploid, grew in soft agar, and formed high-grade tumors in nude mice. Overexpression of CDK15B was detected in 32% of human primary breast cancers tested.

CDK15 phosphatases activate the cell division kinases throughout the cell cycle. Fauman et al., *Cell* 93:617-625 (1998) determined the 2.3-angstrom structure of the human CDK15A catalytic domain. The crystal structure revealed a small alpha/beta domain with a fold unlike previously described phosphatase structures but identical to rhodanese, a sulfur-transfer protein. Only the active-site loop, containing the cys-(X)-5-arg motif, showed similarity to the tyrosine phosphatases. In some crystals, the catalytic cys430 formed a disulfide bond with the invariant cys384, suggesting that CDK15 may be self-inhibited during oxidative stress. Asp383, previously proposed to be the general acid, instead serves a structural role, forming a conserved buried salt bridge. Fauman et al. (1998) proposed that glu431 may act as a general acid.

To protect genome integrity and ensure survival, eukaryotic cells exposed to genotoxic stress cease proliferating to provide time for DNA repair. Mailand et al., *Science* 288:1425-1429 (2000) demonstrated that human cells respond to ultraviolet light or ionizing radiation by rapid, ubiquitin- and proteasome-dependent protein degradation of CDK15A, a phosphatase that is required for progression from G1 to S phase of the cell cycle. This response involved activated CHK1 protein kinase but not the p53 pathway, and the persisting inhibitory tyrosine phosphorylation of CDK2 blocked entry into S phase and DNA replication. CDK15A-dependent cell cycle arrest occurs 1 to 2 hours after ultraviolet radiation, whereas the p53-p21 axis affects the cell cycle only several hours after ultraviolet treatment. The researchers thus concluded that the checkpoint response to DNA damage occurs in 2 waves. Overexpression of CDK15A bypassed the mechanism of cell cycle arrest, leading to enhanced DNA damage and decreased cell survival. Mailand et al. (2000) concluded that the results identified specific degradation of CDK15A as part of the DNA damage checkpoint mechanism and suggested how CDK15A overexpression in human cancers might contribute to tumorigenesis.

CDC7

The CDC7 protein kinase is essential for the G1/S transition and initiation of DNA replication during the cell division cycle in *S. cerevisiae*. Hsk1 is the
5 *S. pombe* CDC7 homolog. By searching EST databases for sequences similar to those of CDC7 and Hsk1, Jiang and Hunter, *Proc. Nat. Acad. Sci.* 94:14320-14325 (1997) identified a partial CDC7 cDNA. They used the partial cDNA to isolate a full-length cDNA from a HeLa cell library. The predicted 574-amino acid human CDC7 protein contains the 11 conserved subdomains found in all protein serine/threonine kinases as
10 well as 3 additional sequences (kinase inserts) between subdomains I and II, VII and VIII, and X and XI. The kinase domains of CDC7 and CDC7 share 44% protein sequence identity. CDC7 has a molecular mass of 64 kD by SDS-PAGE. Using immunofluorescence, the authors demonstrated that CDC7 was predominantly localized in the nucleus. Immune complexes of epitope-tagged CDC7 from mammalian cell
15 lysates phosphorylated histone H1 in vitro. Although the expression levels of CDC7 protein appeared to be constant throughout the cell cycle, the protein kinase activity of CDC7 increased during S phase. Jiang and Hunter (1997) suggested that CDC7 may phosphorylate critical substrate(s) that regulate the G1/S phase transition and/or DNA replication in mammalian cells.

20 Sato et al., *EMBO J.* 16:4340-4351 (1997) isolated cDNAs encoding *Xenopus* and human CDC7 homologs. Northern blot analysis revealed that CDC7 is expressed as 2.4-, 3.5-, and 4.4-kb mRNAs. The 3.5-kb transcript was detected in all tissues tested, while the 2.4-kb mRNA was testis-specific. Sato et al. (1997) determined that CDC7 phosphorylates the MCM2 and MCM3 proteins in vitro,
25 suggesting that CDC7 may regulate DNA replication by modulating MCM functions. Using Northern blot and dot blot analyses, Hess et al. (*Gene* 211:133-140 (1998)) found that CDC7 was expressed in many normal tissues, but was overexpressed in all transformed cell lines tested and in certain tumor types.

30 CDK1

CDK1 is a catalytic subunit of a protein kinase complex, called the M-phase promoting factor, that induces entry into mitosis and is universal among eukaryotes. In the fission yeast *Schizosaccharomyces pombe*, the gene CDK1 is

responsible for controlling the transition from G1 phase to the S phase and from the G2 phase to the M phase of the cell cycle.

Lee et al., (Letter) *Nature* 333:676-679 (1988) described the regulated expression and phosphorylation of the CDK1 homolog in human and murine in vitro systems. While the yeast *cdc2* expression does not appear to be transcriptionally regulated, serum stimulation of human and mouse fibroblasts results in a marked increase in CDK1 transcription. Both the yeast and mammalian systems seem to be regulated by phosphorylation of the CDK1 gene product, a protein kinase of molecular weight 34,000, designated p34(*cdc2*).

10 Draetta et al., *Nature* 336:738-744 (1988) showed that in HeLa cells CDK1 is the most abundant phosphotyrosine-containing protein and its phosphotyrosine content is subject to cell cycle regulation. One site of CDK1 tyrosine phosphorylation in vivo is selectively phosphorylated in vitro by a product of the SRC gene. Liu et al., *Molec. Cell. Biol.* 17: 571-583 (1997) reported that the kinase MYT1
15 also phosphorylates CDK1.

Overexpression of the receptor tyrosine kinase ERBB2 confers Taxol resistance in breast cancers. Yu et al., *Molec. Cell* 2: 581-591 (1998) found that overexpression of ERBB2 inhibits Taxol-induced apoptosis. Taxol activates CDK1 kinase in MDA-MB-435 breast cancer cells, leading to cell cycle arrest at the G2/M
20 phase and, subsequently, apoptosis. A chemical inhibitor of CDK1 and a dominant-negative mutant of CDK1 blocked Taxol-induced apoptosis in these cells. Overexpression of ERBB2 in MDA-MB-435 cells by transfection transcriptionally upregulates CDKN1A which associates with CDK1, inhibits Taxol-mediated CDK1 activation, delays cell entrance to G2/M phase, and thereby inhibits Taxol-induced
25 apoptosis. In CDKN1A antisense-transfected MDA-MB-435 cells or in p21^{-/-} MEF cells, ERBB2 was unable to inhibit Taxol-induced apoptosis. Therefore, CDKN1A participates in the regulation of a G2/M checkpoint that contributes to resistance to Taxol-induced apoptosis in ERBB2-overexpressing breast cancer cells.

ERBB2 overexpression confers resistance to taxol-induced apoptosis by
30 inhibiting p34(CDK1) activation. One mechanism is via ERBB2-mediated upregulation of p21(CIP1), or CDKN1A, which inhibits CDK1. Tan et al., *Molec. Cell* 9:993-1004 (2002) reported that the inhibitory phosphorylation on tyr15 (Y15) of CDK1 was elevated in ERBB2-overexpressing breast cancer cells and primary tumors.

ERBB2 bound to and colocalized with cyclin B-CDK1 complexes and phosphorylated CDK1 Y15. The ERBB2 kinase domain was sufficient to directly phosphorylate CDK1 Y15. Increased CDK1 with phosphorylated Y15 in ERBB2-overexpressing cells corresponded with delayed M phase entry. Expression of a nonphosphorylatable mutant of CDK1 rendered cells more sensitive to taxol-induced apoptosis. Thus, the authors concluded that ERBB2 can confer resistance to taxol-induced apoptosis by directly phosphorylating CDK1.

Konishi et al., *Molec. Cell* 9:1005-1016 (2002) reported that CDK1 is expressed in postmitotic granule neurons of the developing rat cerebellum and that CDK1 mediates apoptosis of cerebellar granule neurons upon the suppression of neuronal activity. They showed that CDK1 catalyzes the phosphorylation of the BAD protein at a distinct site, ser128, and thereby induces BAD-mediated apoptosis in primary neurons by opposing growth factor inhibition of the apoptotic effect of BAD. Phosphorylation of BAD ser128 was found to inhibit the interaction of growth factor-induced ser136-phosphorylated BAD with 14-3-3 proteins.

CDK2

The complex formed of CDK1 and cyclin B is required for the G2-to-M transition in cell division. Human cyclin A binds independently to 2 kinases, CDK1 or CDK2. In adenovirus-transformed cells, the viral E1A oncoprotein seems to associate with CDK2/Cyclin A but not with CDK1/cyclin A. Tsai et al., *Nature* 353: 174-177 (1991) isolated the gene for CDK2, which shares 65% sequence identity with CDK1. They suggested that CDK2 plays a unique role in cell cycle regulation of vertebrate cells.

CDK (e.g., CDK2) activation requires association with cyclins (e.g., CCNE1) and phosphorylation by CAK (CCNH), and leads to cell proliferation. Inhibition of cellular proliferation occurs upon association of CDK inhibitor (e.g., CDKN1B) with a cyclin-CDK complex. Sheaff et al., *Genes Dev.* 11: 1464-1478 (1997) showed that expression of CCNE1-CDK2 at physiologic levels of ATP results in phosphorylation of CDKN1B at thr187, leading to elimination of CDKN1B from the cell and progression of the cell cycle from G1 to S phase. At low ATP levels, the inhibitory functions of CDKN1B are enhanced, thereby arresting cell proliferation.

Apoptosis of human endothelial cells after growth factor deprivation is associated with rapid and dramatic upregulation of cyclin A-associated CDK2 activity. Levkau et al., *Molec. Cell* 1:553-563 (1998) showed that in apoptotic cells the carboxyl-termini of the CDK inhibitors CDKN1A and CDKN1B are truncated by
5 specific cleavage. The enzyme involved in this cleavage is CASP3 and/or a CASP3-like caspase. After cleavage, CDKN1A loses its nuclear localization sequence and exits the nucleus. Cleavage of CDKN1A and CDKN1B resulted in a substantial reduction in their association with nuclear cyclin-CDK2 complexes, leading to a dramatic induction of CDK2 activity. Dominant-negative CDK2, as well as a mutant
10 CDKN1A resistant to caspase cleavage, partially suppressed apoptosis. These data suggested that CDK2 activation, through caspase-mediated cleavage of CDK inhibitors, may be instrumental in the execution of apoptosis following caspase activation.

Hinchcliffe et al., *Science* 283:851-854 (1999) developed a *Xenopus* egg extract arrested in S phase that supported repeated assembly of daughter centrosomes.
15 Multiple rounds of centrosome reproduction were blocked by selective inactivation of CDK2-Cyclin E and were restored by addition of purified CDK2-cyclin E. Confocal microscopy revealed that cyclin E was localized at the centrosome. The authors concluded that CDK2-Cyclin E activity is required for centrosome duplication during S phase and that these results suggested a mechanism that could coordinate centrosome
20 reproduction with cycles of DNA synthesis and mitosis.

Inhibition of CDK2, a positive regulator of eukaryotic cell cycle progression, may represent a therapeutic strategy for prevention of chemotherapy-induced alopecia by arresting the cell cycle and reducing the sensitivity of the epithelium to many cell cycle-active antitumor agents. Davis et al., *Science* 291:134-
25 137 (2001) developed potent small-molecule inhibitors of CDK2 using structure-based methods. Topical application of these compounds in a neonatal rat model of chemotherapy-induced alopecia reduced hair loss at the site of application in 33 to 50% of the animals. Thus, Davis et al. (2001) concluded that inhibition of CDK2 represents a potentially useful approach for the prevention of chemotherapy-induced alopecia in
30 cancer patients.

Falck et al., *Nature Genet.* 30:290-294 (2002) demonstrated that experimental blockade of either the NBS1-MRE11 function or the CHK2-triggered events leads to a partial radioresistant DNA synthesis phenotype in human cells. In

contrast, concomitant interference with NBS1-MRE11 and the CHK2-CDC25A-CDK2 pathways entirely abolishes inhibition of DNA synthesis induced by ionizing radiation, resulting in complete RDS analogous to that caused by defective ATM. In addition, CDK2-dependent loading of CDC45 onto replication origins, a prerequisite for recruitment of DNA polymerase, was prevented upon irradiation of normal or NBS1/MRE11-defective cells but not cells with defective ATM. Falck et al. (2002) concluded that in response to ionizing radiation, phosphorylation of NBS1 and CHK2 by ATM triggers 2 parallel branches of the DNA damage-dependent S-phase checkpoint that cooperate by inhibiting distinct steps of DNA replication.

CDK8

Cyclins are positive regulatory subunits of cyclin-dependent kinases (CDKs). In *S. cerevisiae*, the CDK SRB10 has been shown to interact with SRB11, a cyclin related to mammalian cyclin C. The SRB10-SRB11 complex is part of the RNA polymerase II holoenzyme and acts as a regulator of transcription. To identify human protein kinases with a role in cell cycle control, Schultz and Nigg, *Cell Growth Differ.* 4:821-830 (1993) performed PCR with degenerate oligonucleotides based on conserved motifs in the catalytic domain of the *Aspergillus nidulans* NIMA protein kinase. They isolated 41 distinct promyelocytic leukemia cell line cDNAs, including 1 partial cDNA designated K35. Tassan et al., *Proc. Nat. Acad. Sci.* 92:8871-8875 (1995) noted that K35 appears to be structurally related to CDKs. By screening a human testis cDNA library with K35, they isolated cDNAs corresponding to the entire coding region of CDK8. The predicted 464-amino acid protein contains the sequence motifs and 11 subdomains characteristic of a serine/threonine-specific kinase. The protein sequences of CDK8 and SRB10 are 48% identical over subdomains III to XI, and the 2 proteins have several common features. CDK8 migrates as a 53-kD protein on Western blots of HeLa cell extracts. Coimmunoprecipitation experiments demonstrated that CDK8 interacted with cyclin C both in vitro and in vivo. Tassan et al. (1995) proposed that CDK8-cyclin C might be functionally associated with the mammalian transcription apparatus.

Mammalian CDK8 and cyclin C are components of the RNA polymerase II holoenzyme complex, where they function as a protein kinase that phosphorylates the C-terminal domain of the largest subunit of RNA polymerase II.

The CDK8/cyclin C protein complex is also found in a number of mammalian 'Mediator'-like protein complexes, which repress activated transcription independently of the C-terminal domain in vitro. Akoulitchev et al., *Nature* 407:102-106 (2000) demonstrated that CDK8/cyclin C can regulate transcription by targeting the

5 CDK7/Cyclin H subunits of the general transcription initiation factor IIH. CDK8 phosphorylates mammalian cyclin H at serine 5 and serine 304 both in vitro and in vivo, in the vicinity of its functionally unique N- and C-terminal alpha-helical domains. This phosphorylation represses both the ability of TFIID to activate transcription and its C-terminal kinase activity. In addition, mimicking CDK8 phosphorylation of cyclin H

10 in vivo has a dominant-negative effect on cell growth. Akoulitchev et al. (2000) concluded that their results linked the Mediator complex and the basal transcription machinery by a regulatory pathway involving 2 cyclin-dependent kinases. This pathway appears to be unique to higher organisms.

15 CKS2

The Cks1 protein is a component of the Cdc28 protein kinase in the budding yeast *Saccharomyces cerevisiae*. Richardson et al., *Genes Dev.* 4:1332-1344 (1990) cloned 2 human homologs of the Cks1 gene of yeast. Designated CKS1 and CKS2, both encode proteins of 79 amino acids that share considerable homology at the

20 amino acid level with the products of the corresponding gene in *S. cerevisiae* and another gene in the fission yeast *Schizosaccharomyces pombe*. Both human homologs were capable of rescuing a null mutation of the *S. cerevisiae* Cks1 gene when expressed from the *S. cerevisiae* GAL1 promoter. Linked to Sepharose beads, the CKS1 and CKS2 proteins could bind the CDC28/CDC2 protein kinase from both *S. cerevisiae* and

25 human cells. The CKS1 and CKS2 mRNAs are expressed in different patterns through the cell cycle in HeLa cells, which reflects specialized roles for the encoded proteins.

Spruck et al., *Science* 300: 647-650 (2003) generated mice lacking CKS2 and found them to be viable but sterile in both sexes. Sterility is due to failure of both male and female germ cells to progress past the first meiotic metaphase. The

30 chromosomal events through the end of prophase I are normal in both Cks2-null males and females, suggesting that the phenotype is due directly to failure to enter anaphase and not a consequence of a checkpoint-mediated metaphase I arrest.

CKS1

The Cks1 protein is a component of the Cdc28 protein kinase in the budding yeast *Saccharomyces cerevisiae*. Richardson et al., *Genes Dev.* 4:1332-1344 (1990) cloned 2 human homologs of the Cks1 gene of yeast. Designated CKS1 and
5 CKS2, both encode proteins of 79 amino acids that share considerable homology at the amino acid level with the products of the corresponding gene in *S. cerevisiae* and another gene in the fission yeast *Schizosaccharomyces pombe*. The CKS1 and CKS2 mRNAs were found to be expressed in different patterns through the cell cycle in HeLa cells, which reflects specialized roles for the encoded proteins.

10 Richardson et al. (1990) showed that both human Cks1 homologs were capable of rescuing a null mutation of the *S. cerevisiae* Cks1 gene when expressed from the *S. cerevisiae* GAL1 promoter. Linked to Sepharose beads, the CKS1 and CKS2 proteins could bind the CDC28/CDC2 protein kinase from both *S. cerevisiae* and human cells.

15 By investigating the essential role of CKS1 in *S. cerevisiae*, Morris et al., *Nature* 423:1009-1013 (2003) demonstrated that the protein is primarily involved in promoting mitosis by modulating the transcriptional activation of CDC20. CKS1 is required for both the periodic dissociation of CDC28 kinase from the CDC20 promoter and the periodic association of the proteasome with the promoter. Morris et al. (2003)
20 proposed that the essential role of CKS1 is to recruit the proteasome to, and/or dissociate the CDC28 kinase from, the CDC20 promoter, thus facilitating transcription by remodeling transcriptional complexes or chromatin associated with the CDC20 gene.

25 Bourne et al., *Cell* 84:863-874 (1996) analyzed the crystal structure of the CDK-CKS1 complex and defined the critical protein domains involved in the interaction of the 2 molecules. They tested the biologic importance of the structure-based model by constructing mutant alleles of CKS1 that led to decreased interaction with CDK2. Bourne et al. (1996) concluded that the structural analysis revealed the mode of CDK2 binding to CKS1, suggested a possible mechanism of cooperativity and
30 self regulation of CKS proteins during the cell cycle, and implicated CKS as a targeting or matchmaking protein for CDK and at least 1 other phosphoprotein.

CUL1

Kipreos et al., *Cell* 85:829-839 (1996) found that mutations in the cullin-1 (cul1) gene of *C. elegans* cause hyperplasia of all tissues. They determined that cul1 is a negative regulator of the cell cycle; in cul1 mutants, the G1-to-S-phase progression is accelerated, overriding mechanisms for mitotic arrest and producing abnormally small cells. Searches of EST databases revealed that cul1 is a member of a conserved gene family, with at least 5 members in nematodes, 6 in humans, and 3 in *S. cerevisiae*. Human CUL1 is an ortholog of nematode cul1.

Michel and Xiong, *Cell Growth Differ.* 9:435-449 (1998) stated that CUL1 has homology to yeast Cdc53, which is part of a complex known as SCF that mediates the ubiquitin-dependent degradation of G1 cycles and cyclin-dependent kinase inhibitors. SCF complexes are composed of SKP1, Cdc53, and an F box-containing protein, which may confer substrate specificity. These authors found that interaction of the predicted 776-amino acid human CUL1 protein with SKP1 is mediated through the N-terminal domains of both proteins. Immunoprecipitation studies and Western blot analysis revealed that the steady-state levels of both CUL1 and SKP1, as well as their association with one another, remain relatively constant throughout the cell cycle and in postmitotic cells. However, none of the other human cullins tested interacted with SKP1. Michel and Xiong (1998) determined that via SKP1, CUL1 forms a complex with SKP2, an F box-containing protein, and cyclin A. The authors concluded that the SCF proteolytic pathway is evolutionarily conserved and is used by mammalian CUL1, while the other cullin proteins may use a SKP1/F-box-independent pathway to mediate protein degradation.

Maniatis, *Genes Dev.* 13: 505-510 (1999) reviewed the work of Winston et al., *Genes Dev.* 13:270-283 (1999) and others concerning the SCF ubiquitin ligase complex. CUL1 acts as a scaffold for SKP1 and the F-box-containing BTRC protein in the SCF complex, which regulates the function of nuclear factor kappa-B and beta-catenin.

Yu et al., *Proc. Nat. Acad. Sci.* 95:11324-11329 (1998) reported studies suggesting that the p19 (SKP1)/p45 (SKP2)/CUL1 complex is likely to function as a conserved ubiquitin E3 enzyme that regulates the mammalian G1/S transition by specifically targeting mammalian G1 cell cycle regulators, such as p21 and cyclin D proteins, for ubiquitin-dependent degradation.

The sequential timing of cell cycle transitions is primarily governed by the availability and activity of key cell cycle proteins. Studies in yeast identified a class of ubiquitin ligases (E3 enzymes) called SCF complexes, which regulate the abundance of proteins that promote and inhibit cell cycle progression at the transition between G1 and S phases. SCF complexes consist of 3 invariable components, SKP1, CUL1 (CDC53 in yeast), and RBX1, and a variable F-box protein that recruits a specific cellular protein to the ubiquitin pathway for degradation. To study the role of CUL1 in mammalian development and cell cycle regulation, Dealy et al., *Nature Genet.* 23:245-248 (1999) generated mice deficient for Cull1 and analyzed null embryos and heterozygous cell lines. They showed that Cull1 is required for early mouse development and that Cull1 mutants fail to regulate the abundance of the G1 cyclin, cyclin E1, during embryogenesis.

Zheng et al., *Molec. Cell* 10:1519-1526 (2002) determined that the majority of CUL1 is in a complex with CAND1 and ROC1 independent of SKP1 and the F box protein SKP2. Both in vivo and in vitro, CAND1 prevented binding of SKP1 and SKP2 to CUL1, while dissociation of CAND1 from CUL1 promoted the reverse reaction. Neddylation of CUL1 or the presence of SKP1 and ATP caused CAND1 dissociation. These data suggested that CAND1 regulates the formation of the SCF complex and that its dissociation from CUL1 is coupled with the incorporation of F box proteins into the SCF complex, causing their destabilization.

Liu et al., *Molec. Cell* 10:1511-1518 (2002) showed that CAND1 selectively binds to unneddylated CUL1 and is dissociated by CUL1 neddylation. CAND1 formed a ternary complex with CUL1 and ROC1. It dissociated SKP1 from CUL1 and inhibited SCF ligase activity in vitro. Suppression of CAND1 in vivo increased the level of the CUL1-SKP1 complex. The authors concluded that, by restricting SKP1-CUL1 interaction, CAND1 regulates the assembly of productive SCF ubiquitin ligases, allowing a common CUL1-ROC core to be utilized by a large number of SKP1-F box-substrate subcomplexes.

Staropoli et al., *Neuron* 37:735-749 (2003) demonstrated that parkin associates with the F-box proteins FBXW7 and CUL1 in a distinct ubiquitin ligase complex. FBXW7 serves to target the ligase activity to cyclin E, a protein previously implicated in the regulation of neuronal apoptosis. In cells transfected with the parkin T240R mutation, parkin deficiency potentiated the accumulation of cyclin E in cultured

postmitotic neurons exposed to the glutamatergic excitotoxin kainate and promoted their apoptosis. Furthermore, parkin overexpression attenuated cyclin E accumulation in toxin-treated neurons and protected them from apoptosis.

5

CUL2

Kipreos et al., *Cell* 85:829-839 (1996) identified a conserved gene family, designated cullins, with at least 5 members in nematodes, 6 in humans, and 3 in *S. cerevisiae*. Human CUL2 is an ortholog of nematode cul2. Michel and Xiong, *Cell Growth Differ.* 9: 435-449 (1998) identified human CUL2 cDNAs and reported that the predicted protein is 745 amino acids long.

10

Pause et al., *Proc. Nat. Acad. Sci.* 94:2156-2161 (1997) reported that the protein sequences of human and *C. elegans* cul2 are 45% identical. Using immunofluorescence, they showed that CUL2 is a cytosolic protein that can be translocated to the nucleus by VHL. Both Pause et al. (1997) and Lonergan et al., *Molec. Cell. Biol.* 18: 732-741 (1998) found that CUL2 specifically associates with the trimeric VHL-elongin B-elongin C, or VBC, complex in vitro and in vivo. This association was disrupted by mutations in VHL that disrupt elongin binding. Nearly 70% of the naturally-occurring cancer-disposing mutations in VHL abrogate elongin binding, suggesting that binding to elongin-CUL2 complexes contributes to the ability of VHL to suppress tumor growth in vivo. Pause et al. (1997) suggested that CUL2 is a candidate tumor suppressor gene, as has been proposed for CUL1. Lonergan et al. (1998) demonstrated that formation of the VBC-CUL2 complexes is linked to the regulation of hypoxia-inducible mRNAs by VHL. They proposed a model for this regulation based on the similarity of elongin C and CUL2 to SKP1 and CUL1, which have been shown in yeast to form complexes that target specific proteins for ubiquitin-dependent proteolysis.

15

20

25

CUL3

Kipreos et al., *Cell* 85:829-839 (1996) identified a conserved gene family, designated cullins, with at least 5 members in nematodes, 6 in humans, and 3 in *S. cerevisiae*. Human CUL3 is an ortholog of nematode cul3. Michel and Xiong, *Cell Growth Differ.* 9:435-449 (1998) identified human CUL3 cDNAs and reported that the predicted protein is 768 amino acids long. Ishikawa et al., *DNA Res.* 5:169-176 (1998)

30

isolated a CUL3 cDNA, KIAA0617, as 1 of 100 brain cDNAs encoding large proteins. Using RT-PCR, they found that CUL3 is expressed in several tissues. Du et al., *J. Biol. Chem.* 273:24289-24292 (1998) identified CUL3 as a gene whose expression in human fibroblasts is induced by phorbol 12-myristate 13-acetate (PMA) and suppressed by salicylate. They reported that the sequences of the human and *C. elegans* cul3 proteins share 46% identity. Northern blot analysis revealed that CUL3 is expressed as major 2.8- and minor 4.3-kb transcripts in various human tissues, with the highest levels in skeletal muscle and heart.

10 E2F-3

The E2F family of transcription factors activate genes that control DNA synthesis (Chellappan et al., *Cell* 65:1053 (1991), which is hereby incorporated by reference in its entirety). Cyclin E2 is rate limiting for G1 progression and its expression is regulated by E2F. E2F is a pivotal role in coordination of events connected with proliferation, cell cycle arrest, and apoptosis. E2F transcription factors also regulate cyclin A gene expression. Cyclins E and A are known to be active in G1 phase, which is the interval that cells respond to extracellular stimuli. G1 regulators are important in accelerating or braking the cell cycle (Sherr, *Cancer Res.* 60:3689 (2000), which is hereby incorporated by reference in its entirety). Because increased BVR expression has been shown to upregulate cyclins A, E1 and E2, as well as the transcription factor E2F-3, it is believed that BVR can be used to control the cell division cycle and alter periods associated with DNA replication, thus allowing for DNA repair and cell differentiation.

MYC induces transcription of the E2F1, E2F2, and E2F3 genes. Using primary mouse embryo fibroblasts deleted for individual E2f genes, Leone et al., *Molec. Cell* 8:105-113 (2001) showed that MYC-induced S phase and apoptosis requires distinct E2F activities. The ability of Myc to induce S phase was impaired in the absence of either E2f2 or E2f3 but not E2f1 or E2f4. In contrast, the ability of Myc to induce apoptosis was markedly reduced in cells deleted for E2f1 but not E2f2 or E2f3. The authors proposed that the induction of specific E2F activities is an essential component in the MYC pathways that control cell proliferation and cell fate decisions.

The retinoblastoma tumor suppressor (Rb) pathway is believed to have a critical role in the control of cellular proliferation by regulating E2F activities. E2F1,

E2F2, and E2F3 belong to a subclass of E2F factors thought to act as transcriptional activators important for progression through the G1/S transition. Wu et al., *Nature* 414: 457-462 (2001) used a conditional gene targeting approach to demonstrate that combined loss of these 3 E2F factors severely affects E2F target expression and completely abolishes the ability of mouse embryonic fibroblasts to enter S phase, progress through mitosis, and proliferate. Loss of E2F function results in elevation of CIP1 protein, leading to a decrease in cyclin-dependent kinase activity and Rb phosphorylation. Wu et al. (2001) concluded that these findings suggest a function for this subclass of E2F transcriptional activators in a positive feedback loop, through downmodulation of CIP1, that leads to the inactivation of Rb-dependent repression and S phase entry.

By targeting the entire subclass of E2F transcriptional activators, Wu et al. (2001) provided direct genetic evidence for their essential role in cell cycle progression, proliferation, and development. Wu et al. (2001) initially generated and interbred E2f1, E2f2, and E2f3 mutant mice, and found that although mice null for E2f1 and E2f2 were viable and developed to adulthood, mice null for E2f1 and E2f3 or E2f2 and E2f3 died early during embryonic development, at or just before embryonic day 9.5, pointing to a central role for E2f3 in mouse development.

Cloud et al., *Molec. Cell. Biol.* 22:2663-2672 (2002) generated E2f3-null mice. They found that E2f3 was essential for embryonic viability in the pure 129/Sv background, but that the presence of C57BL/6 alleles yielded some adult survivors. Although growth retarded, surviving E2f3 -/- animals were initially healthy and exhibited no obvious tumor phenotype. They died prematurely, however, with signs typical of congestive heart failure, a defect completely distinct from those reported in E2f1-null mice. Cloud et al. (2002) also generated E2f1/E2f3 compound mutant mice and found that almost all of the developmental and age-related defects arising in the individual E2f1- or E2f3-null mice were exacerbated by the mutation of the other E2f.

MAD2L1

Li and Benezra, *Science* 274:246-248 (1996) reviewed mitotic checkpoint control mechanisms and noted that these mechanisms check the cells preparedness to undergo division. Through these mechanisms cell cycle progression is blocked before the irreversible events associated with anaphase if either the mitotic

spindle apparatus is not properly assembled or the kinetochore is not properly attached to the spindle. Mitotic arrest-deficient-2 (MAD2) is one of 6 yeast genes that are required for execution of the mitotic checkpoint. Dysfunction of MAD2 may lead to malignancy or degeneration of cells (Li and Nicklas, *Nature* 373: 630-632 (1995); Li and Benezra, *Science* 274: 246-248 (1996)).

Li and Benezra (1996) isolated a human homolog of MAD2 (MAD2L1) in a screen for high copy-number suppressors of thiabendazole sensitivity in yeast lacking CBF1, a component of the kinetochore. (Thiabendazole is a mitotic spindle assembly inhibitor.) The gene encodes a 205-amino acid polypeptide. DNA sequence determination revealed that the open reading frame of the human clone is 60% identical to the yeast MAD2 gene. They used antibody electroporation experiments to demonstrate that the human MAD2 gene was a necessary component of the mitotic checkpoint in HeLa cells. Through immunofluorescence studies they demonstrated that the human MAD2 protein is localized at the kinetochore after chromosome condensation but that it is no longer observed at the kinetochore in metaphase. Based on this observation they proposed that MAD2 monitors the completeness of the spindle kinetochore attachment. Li and Benezra (1996) demonstrated that a human breast tumor cell line T47D has reduced MAD2 expression and that it failed to arrest in mitosis after nocodazole treatment. They proposed that loss of MAD2 function might also lead to aberrant chromosome segregation in mammalian cells.

Chen et al., *Science* 274:242-245 (1996) isolated a *Xenopus* homolog of yeast MAD2. They reported that the product of this gene plays an essential role in spindle checkpoint assembly. The protein associated with unattached kinetochores in prometaphase and nocodazole treated cells and disappeared from kinetochores at metaphase.

Luo et al., *Molec. Cell* 9:59-71 (2002) showed that RNA interference-mediated suppression of MAD1 function in mammalian cells caused loss of MAD2 kinetochore localization and impairment of the spindle checkpoint. MAD1 and CDC20 contain MAD2-binding motifs that share a common consensus, and the authors identified a class of MAD2-binding peptides (MBPs) with a similar consensus. Binding of one of these ligands, MBP1, triggered an extensive rearrangement of the tertiary structure of MAD2. MAD2 also underwent a similar striking structural change upon binding to a MAD1 or CDC20 binding motif peptide. These data suggested that,

upon checkpoint activation, MAD1 recruits MAD2 to unattached kinetochores and may promote binding of MAD2 to CDC20.

The initiation of chromosome segregation at anaphase is linked by the spindle assembly checkpoint to the completion of chromosome-microtubule attachment during metaphase. To determine the function of the Mad2 protein during normal cell division, Dobles et al., *Cell* 101:635-645 (2000) knocked out the Mad2 gene in mice. They found that embryonic cells lacking Mad2 at embryonic day 5.5, like mad2 yeast, grew normally but were unable to arrest in response to spindle disruption. At embryonic day 6.5, the cells of the epiblast began rapid cell division, and the absence of a checkpoint resulted in widespread chromosome missegregation and apoptosis. In contrast, the postmitotic trophoblast giant cells survived without Mad2. Thus, the spindle assembly checkpoint is required for accurate chromosome segregation in mitotic mouse cells and for embryonic viability, even in the absence of spindle damage.

Shonn et al., *Science* 289: 300-303 (2000) characterized the spindle checkpoint in meiosis of *S. cerevisiae* by comparing wildtype and mad2-deficient yeast. In the absence of the checkpoint, the frequency of meiosis I missegregation increased with increasing chromosome length, reaching 19% for the longest chromosome. Meiosis I nondisjunction in spindle checkpoint mutants could be prevented by delaying the onset of anaphase. In a recombinant-defective mutant, the checkpoint delayed the biochemical events of anaphase I, suggesting that chromosomes that are attached to microtubules but are not under tension can activate the spindle checkpoint. Spindle checkpoint mutants reduced the accuracy of chromosome segregation in meiosis I much more than that in meiosis II, suggesting that checkpoint defects may contribute to Down syndrome. Shonn et al. (2000) showed that the budding yeast spindle checkpoint, which is largely dispensable in wildtype mitosis, plays a critical role in meiotic chromosome segregation. They suggested that the difference may reflect the different chromosome linkages in mitosis and meiosis I. In mitosis, sister chromatid cohesion forces sister kinetochores to face opposite spindle poles. In meiosis I, homologs are linked at sites of recombination that can be far from the kinetochores, creating a floppy linkage. If the nearest recombination event is further from the centromere on long chromosomes, this idea may explain why long chromosomes preferentially nondisjoin in checkpoint-defective cells.

Michel et al., *Nature* 409:355-359 (2001) reported that deletion of one MAD2 allele results in a defective mitotic checkpoint in both human cancer cells and murine primary embryonic fibroblasts. Checkpoint-defective cells show premature sister chromatid separation in the presence of spindle inhibitors and an elevated rate of chromosome missegregation events in the absence of these agents. Furthermore, Mad2 +/- mice develop lung tumors at high rates after long latencies, implicating defects in the mitotic checkpoint in tumorigenesis.

MCM6

The MCM genes were originally identified in yeast defective in minichromosome maintenance and have since been shown to play roles in the progression of the cell cycle; many are cell division control genes. MCMs 2 through 7 are thought to be 'DNA licensing factors' which bind to the DNA after mitosis and enable DNA replication before being removed during S phase. Harvey et al., *FEBS Lett.* 398: 135-140 (1996) identified the human MCM6 gene and mapped it to 2q21 by fluorescence in situ hybridization. MCM6 is expressed in a wide variety of human adult and fetal tissues.

RBX1

The VHL protein is part of a complex that includes elongin B, elongin C, and cullin-2(CUL2), proteins associated with transcriptional elongation and ubiquitination. Components of the VCB (VHL-elongin C/elongin B) complex share sequence similarities with the E3 ubiquitin ligase complexes, SCF (SKP1)-CUL1-F-box protein) and APC (anaphase promoting complex). F-box proteins, such as S. cerevisiae Cdc4 and Grr1, are adaptor proteins that recruit different binding partners to SCF (Tyers and Willems, *Science* 284: 602-604 (1999)).

Kamura et al., *Science* 284:657-661 (1999) purified the endogenous VHL complex from rat liver and determined the partial protein sequence of a 16-kD protein component. By searching an EST database with the peptide sequences, these authors identified human and mouse cDNAs encoding a predicted 108-amino acid protein. They designated the protein RBX1 (RING-box protein-1) because it contained a RING-H2 finger-like motif. The mouse and human RBX1 proteins are identical, and there are RBX1 homologs in *Drosophila*, *C. elegans*, and *S. cerevisiae*. Kamura et al.

(1999) demonstrated that RBX1 interacts with both CUL1 and CUL2. They found that yeast Rbx1 is a subunit and a potent activator of the SCF-Cdc4 complex that is required for ubiquitination of the cyclin-dependent kinase inhibitor Sic1 and for the G1-to-S cell cycle transition. Mammalian RBX1 rescued the viability defect in yeast *rbx1* mutants.

- 5 The authors concluded that the presence of RBX1 as a component of both the VHL and SCF-Cdc4 complexes extends the structural similarity between these 2 complexes and raises the possibility that the VHL complex may function as a ubiquitin ligase for target proteins. Skowyra et al., *Science* 284: 662-665 (1999) found that Rbx1 is part of the yeast SCF-Grr1 complex, which ubiquitinates the phosphorylated G1 cyclin *cln1*.

- 10 Using mouse cullin-4A as bait in a yeast 2-hybrid screen of a human HeLa pGAD cDNA library, Ohta et al., *Molec. Cell* 3:535-541 (1999) identified 2 highly conserved RING finger proteins, which they referred to as ROC1 and ROC2 (RBX1 and RBX2), which are homologous to APC11, a subunit of the anaphase-promoting complex. The RBX1 and RBX2 proteins commonly interact with all cullins.
- 15 Yeast RBX1 encodes an essential gene whose reduced expression resulted in multiple, elongated buds and accumulation of Sic1 and Cln2 proteins. RBX1 and APC11 immunocomplexes can catalyze isopeptide ligations to form polyubiquitin chains in an E1- and E2-dependent manner. RBX1 mutations completely abolished their ligase activity without noticeable changes in associated proteins. Ubiquitination of
- 20 phosphorylated I-kappa-B-alpha can be catalyzed by the RBX1 immunocomplex in vitro. Hence, combinations of RBX/APC11 and cullin proteins potentially constitute a wide variety of ubiquitin ligases.

RAD50

- 25 The *S. cerevisiae* Rad50 gene encodes a protein that is essential for double-stranded DNA break repair by nonhomologous DNA end joining and chromosomal integration. The yeast Rad50, Mre11, and Xrs2 proteins appear to act in a multiprotein complex, consistent with the observation that mutations in these genes confer nearly identical phenotypes of no meiotic recombination and elevated rates of
- 30 homologous mitotic recombination. By direct selection of cDNAs from the 5q23-q31 chromosomal interval, Dolganov et al., *Molec. Cell Biol.* 16:4832-4841 (1996) isolated a cDNA encoding a human Rad50 homolog. The human RAD50 gene spans 100 to 130 kb. Northern blot analysis revealed that the RAD50 gene was expressed as a 5.5-

kb mRNA predominantly in testis. A faint 7-kb transcript, which the authors considered to be an mRNA with an alternatively processed 3-prime end, was also detected. Yeast Rad50 and the predicted 1,312-amino acid human RAD50 protein share more than 50% identity in their N- and C-termini. The central heptad repeat domains of the proteins have relatively divergent primary sequences but are predicted to adopt very similar coiled-coil structures. Using immunoprecipitation, Dolganov et al. (1996) demonstrated that the 153-kD RAD50 is stably associated with MRE11 in a protein complex, which may also include proteins of 95 kD, 200 kD, and 350 kD.

By inclusion within mapped clones and by analysis of somatic cell hybrids, Dolganov et al. (1996) mapped the RAD50 gene to 5q31. They suggested that a recombinational DNA repair deficiency may be associated with the development of myeloid leukemia, since this chromosomal region is frequently altered in acute myeloid leukemia and myelodysplastic disease.

Trujillo et al., *J. Biol. Chem.* 273:21447-21450 (1998) determined that the 95-kD protein in the mammalian cell nuclear complex containing RAD50 and MRE11 is nibrin, or p95, the protein encoded by the gene mutated in Nijmegen breakage syndrome (NBS). The RAD50 complex possessed manganese-dependent single-stranded DNA endonuclease and 3-prime to 5-prime exonuclease activities. The authors stated that these nuclease activities are likely to be important for recombination, repair, and genomic stability. Carney et al., *Cell* 93:477-486 (1998) demonstrated that p95 is an integral member of the MRE11/RAD50 complex and that the function of this complex is impaired in cells from NBS patients. They stated that although p95 has little sequence homology to yeast Xrs2, the 2 proteins can be considered functional analogs since they link the conserved activities of MRE11/RAD50 to the cellular DNA damage response in their respective organisms.

Zhong et al., *Science* 285:747-750 (1999) showed that BRCA1 interacts in vitro and in vivo with RAD50. Formation of irradiation-induced foci positive for BRCA1, RAD50, MRE11, or p95 was dramatically reduced in HCC/1937 breast cancer cells carrying a homozygous mutation in BRCA1 but was restored by transfection of wildtype BRCA1. Ectopic expression of wildtype, but not mutated, BRCA1 in these cells rendered them less sensitive to the DNA damage agent methyl methanesulfonate. These data suggested to the authors that BRCA1 is important for the cellular responses to DNA damage that are mediated by the RAD50-MRE11-p95 complex.

Wang et al., *Genes Dev.* 14:927-939 (2000) used immunoprecipitation and mass spectrometry analyses to identify BRCA1-associated proteins. They found that BRCA1 is part of a large multisubunit protein complex of tumor suppressors, DNA damage sensors, and signal transducers. They named this complex BASC, for
5 'BRCA1-associated genome surveillance complex.' Among the DNA repair proteins identified in the complex were ATM, BLM, MSH2, MSH6, MLH1, the RAD50-MRE11-NBS1 complex, and the RFC1-RFC2-RFC4 complex. Confocal microscopy demonstrated that BRCA1, BLM, and the RAD50-MRE11-NBS1 complex colocalize to large nuclear foci. Wang et al. (2000) suggested that BASC may serve as a sensor of
10 abnormal DNA structures and/or as a regulator of the postreplication repair process.

Telomeres allow cells to distinguish natural chromosome ends from damaged DNA and protect the ends from degradation and fusion. In human cells, telomere protection depends on the TTAGGG repeat-binding factor, TRF2, which may remodel telomeres into large duplex loops (t-loops). Zhu et al., *Nature Genet.* 25:347-
15 352 (2000) showed by nanoelectrospray tandem mass spectrometry that RAD50 protein is present in TRF2 immunocomplexes. Coimmunoprecipitation studies showed that a small fraction of RAD50, MRE11, and p95 is associated with TRF2. Indirect immunofluorescence demonstrated the presence of RAD50 and MRE11 at interphase telomeres. NBS1 was associated with TRF2 and telomeres in S phase, but not in G1 or
20 G2. Although the MRE11 complex accumulated in irradiation-induced foci (IRIFs) in response to gamma-irradiation, TRF2 did not relocate to IRIFs and irradiation did not affect the association of TRF2 with the MRE11 complex, arguing against a role for TRF2 in double-strand break repair. Zhu et al. (2000) proposed that the MRE11 complex functions at telomeres, possibly by modulating t-loop formation.

25 The MRE11/RAD50 protein complex functions in diverse aspects of the cellular response to double strand breaks (DSBs), including the detection of DNA damage, the activation of cell cycle checkpoints, and DSB repair. Whereas genetic analyses in *S. cerevisiae* have provided insight regarding DSB repair functions of this highly conserved complex, the implication of the human complex in Nijmegen
30 breakage syndrome reveals its role in cell cycle checkpoint functions. Luo et al., *Proc. Nat. Acad. Sci.* 96:7376-7381 (1999) established mice with mutation in the mouse Rad50 gene and examined the role of the Mre11/Rad50 protein complex in the DNA damage response. Early embryonic cells deficient in Rad50 were hypersensitive to

ionizing radiation, consistent with a role for this complex in the repair of ionizing radiation-induced DSBs. However, the null Rad50 mutation was lethal in cultured embryonic stem cells and in early developing embryos, indicating that the mammalian protein complex mediates functions in normally growing cells that are essential for viability.

In mammalian cells, a conserved multiprotein complex of MRE11, RAD50, and NBS1 is important for double-strand break repair, meiotic recombination, and telomere maintenance. In the absence of the early region E4, the double-stranded genome of adenoviruses is joined into concatamers too large to be packaged. Stracker et al., *Nature* 418:348-352 (2002) investigated the cellular proteins involved in the concatamer formation and how they are inactivated by E4 products during a wildtype infection. They demonstrated that concatamerization requires functional MRE11 and NBS1, and that these proteins are found at foci adjacent to viral replication centers. Infection with wildtype virus results in both reorganization and degradation of members of the MRE11-RAD50-NBS1 complex. These activities are mediated by 3 viral oncoproteins that prevent concatamerization. This targeting of cellular proteins involved in the genomic stability suggested a mechanism for 'hit-and-run' transformation observed for these viral oncoproteins.

Hopfner et al., *Nature* 418: 562-566 (2002) presented a 2.2-angstrom crystal structure of the Rad50 coiled-coil region that revealed an unexpected dimer interface at the apex of the coiled coils in which pairs of conserved cys-x-x-cys motifs form interlocking hooks that bind one zinc ion. Biochemical, x-ray, and electron microscopy data indicated that these hooks can join oppositely protruding Rad50 coiled-coil domains to form a flexible bridge of up to 1,200 angstroms. This suggested a function for the long insertion in the Rad50 ABC-ATPase. The Rad50 hook is functional, since mutations in this motif confer radiation sensitivity in yeast and disrupt binding at the distant Mre11 nuclease interface. Hopfner et al. (2002) concluded that their data support an architectural role for the Rad50 coiled coils in forming metal-mediated bridging complexes between 2 DNA-binding heads. The resulting assemblies have appropriate lengths and conformational properties to link sister chromatids in homologous recombination and DNA ends in nonhomologous end-joining.

Human cell division is regulated primarily at the G1-to-S or the G2-to-M boundaries. The sequential activation of cyclin-dependent kinases (CDKs) and their subsequent phosphorylation of critical substrates promote orderly progression through the cell cycle. The complexes formed by CDK4 and the D-type cyclins (e.g., D1; D2; 5 D3) are involved in the control of cell proliferation during the G1 phase. CDK4 is inhibited by p16, also known as cyclin-dependent kinase inhibitor-2 (CDKN2A).

Harbour et al., *Cell* 98:859-869 (1999) presented evidence that phosphorylation of the C-terminal region of RB by CDK4/CDK6 initiates successive intramolecular interactions between the C-terminal region and the central pocket. The 10 initial interaction displaces histone deacetylase from the pocket, blocking active transcriptional repression by RB. This facilitates a second interaction that leads to phosphorylation of the pocket by CDK2 and disruption of pocket structure. These intramolecular interactions provide a molecular basis for sequential phosphorylation of RB by CDK4/CDK6 and CDK2. CDK4/CDK6 is activated early in G1, blocking 15 active repression by RB. However, it is not until near the end of G1, when cyclin E is expressed and CDK2 is activated, that RB is prevented from binding and inactivating E2F.

Modiano et al., *J. Immun.* 165:6693-6702 (2000) found that 5 of 16 healthy individuals expressed CDK4 mRNA, protein, and activity in unstimulated 20 peripheral blood T cells and that these T cells proliferated directly in response to interleukin-2 (IL2) in the absence of mitogens. In cells from these individuals, CDK4 expression and activity were resistant to protein kinase inhibitors, unlike stimulated cells from individuals lacking basal CDK4 expression. The phenotype of the T cells of these individuals was comparable to that observed in a human IL2-dependent T-cell 25 line. Modiano et al. (2000) proposed that CDK4 activity may be a useful marker for cytokine responsiveness in T cells.

In primary epidermal cells, Lazarov et al., *Nature Med.* 8:1105-1114 (2002) found that oncogenic RAS transiently decreases CDK4 expression in association with cell cycle arrest in the G1 phase. CDK4 coexpression circumvents RAS growth 30 suppression and induces invasive human neoplasia resembling squamous cell carcinoma. Tumorigenesis is dependent on CDK4 kinase function, with cyclin D1 required but not sufficient for this process. In facilitating escape from G1 growth restraints, RAS and CDK4 alter the composition of cyclin D and cyclin E complexes

Zou et al., *Genes Dev.* 16: 2923-2934 (2002) noted that Cdk4 null mice are viable, but they exhibit diabetes mellitus due to degeneration of pancreatic beta cells, as well as growth retardation and infertility due to severe hypoplasia and dysfunction of the pituitary. Embryonic fibroblasts from Cdk4 null mice initially proliferate at normal rates, but they display a 4- to 5-hour delay in reentry into the cell cycle following quiescence. Zou et al. (2002) found that Cdk4 was required for Ras-mediated transformation, and Cdk4 disruption led to senescence that was independent of Arf or p53. Senescence was associated with increased Cdkn1a stability.

Weinstein et al., *Molec. Cell Biol.* 14: 3350-3363 (1994) identified a protein, designated p55CDC or CDC20, that is homologous to the *S. cerevisiae* cell division cycle 20 protein, in cycling mammalian cells. This transcript is detectable in

all exponentially growing cell lines but disappears when cells are chemically induced to differentiate. The p55CDC protein is essential for cell division. Immunoprecipitation of p55CDC yielded protein complexes with kinase activity that fluctuated during the cell cycle. Since p55CDC did not have the conserved protein kinase domains, this
5 activity must be due to one or more of the associated proteins in the immune complex. The highest levels of protein kinase activity were seen with alpha-casein and myelin basic protein as substrates and demonstrated a pattern of activity distinct from that described for the known cyclin-dependent cell division kinases. The p55CDC protein was also phosphorylated in dividing cells. The 499-amino acid sequence of p55CDC
10 contains 7 repeats homologous to the beta subunit of G proteins. The highest degree of homology in these repeats was found with the *S. cerevisiae* Cdc20 and Cdc4 proteins, which have been proposed to be involved in the formation of a functional bipolar mitotic spindle in yeast cells. The G beta repeat has been postulated to mediate protein-protein interactions and, in p55CDC, may modulate its association with a unique cell
15 cycle protein kinase.

CDC20 is a component of the mammalian cell cycle mechanism. Activation of the anaphase-promoting complex (APC) is required for anaphase initiation and for exit from mitosis. Fang et al., *Molec. Cell* 2:163-171 (1998) showed that APC was activated during mitosis and G1 by 2 regulatory factors, CDC20 and
20 HCDH1. These proteins directly bind to APC and activate its cyclin ubiquitination activity. CDC20 confers a strict destruction-box (D-box) dependence on APC, while HCDH1 shows a much more relaxed specificity for the D-box. In HeLa cells, the protein levels of CDC20 as well as its binding to APC peak in mitosis and decrease drastically at early G1. Thus, CDC20 is the mitotic activator of APC and directs the
25 degradation of substrates containing the D-box.

By investigating the essential role of CKS1 in *S. cerevisiae*, Morris et al., *Nature* 423:1009-1013 (2003) demonstrated that the protein is primarily involved in promoting mitosis by modulating the transcriptional activation of CDC20. CKS1 is required for both the periodic dissociation of CDC28 kinase from the CDC20 promoter
30 and the periodic association of the proteasome with the promoter. Morris et al. (2003) proposed that the essential role of CKS1 is to recruit the proteasome to, and/or dissociate the CDC28 kinase from, the CDC20 promoter, thus facilitating transcription

by remodeling transcriptional complexes or chromatin associated with the CDC20 gene.

Luo et al., *Molec. Cell* 9:59-71 (2002) showed that RNA interference-mediated suppression of MAD1 function in mammalian cells caused loss of MAD2
5 kinetochore localization and impairment of the spindle checkpoint. MAD1 and CDC20 contain MAD2-binding motifs that share a common consensus, and the authors identified a class of MAD2-binding peptides (MBPs) with a similar consensus. Binding of one of these ligands, MBP1, triggered an extensive rearrangement of the tertiary structure of MAD2. MAD2 also underwent a similar striking structural change
10 upon binding to a MAD1 or CDC20 binding motif peptide. These data suggested that, upon checkpoint activation, MAD1 recruits MAD2 to unattached kinetochores and may promote binding of MAD2 to CDC20.

RPL13A

15 Adams et al., *Hum. Molec. Genet.* 1:91-96 (1992) identified a novel cDNA representing an mRNA showing significantly higher levels of expression in benign breast lesions than in carcinomas. In both tissues, the expression was highest in epithelial cells as determined by in situ hybridization to tissue sections. The protein deduced from the nucleotide sequence was highly basic with no signal or
20 transmembrane sequence, but 2 potential nuclear localization signals. No significant homology was found with known DNA or protein sequences. The cDNA hybridized to multiple sequences within both human and other mammalian genomes and to single genomic sequences in *Drosophila*, *Physarum*, and *Schizosaccharomyces pombe*. Thus the cDNA represents a highly conserved gene sequence. Only one major transcript was
25 identified in human cells, but the existence of several pseudogenes was suspected.

Thus, one aspect of the present invention relates to methods of modifying cell cycle or cell signaling pathways. These are achieved by modifying the nuclear or cellular concentration of BVR (or fragments or variants thereof) in a cell,
30 whereby an increase in the nuclear concentration of biliverdin reductase, or fragments or variants thereof, increases the expression levels of certain cell cycle or cell signaling proteins and decreases the expression levels of other cell cycle or cell signaling proteins; whereas a decrease in the nuclear or cellular concentration of biliverdin

reductase, or fragments or variants thereof, decreases the expression levels of certain cell cycle or cell signaling proteins and increases the expression levels of other cell cycle or cell signaling proteins.

Altering the expression level of cell cycle or cell signaling proteins by
5 modifying the nuclear or cellular concentration of BVR (or fragments or variants thereof) in a cell may implicate various diseases. For example, dysregulation of apoptosis can lead to various diseases and disorders. It is now well-known that reduced apoptosis may contribute to tumorigenesis and formation of cancer. Thus, induction of tumor cell apoptosis can be an effective approach in treating cancer. In addition,
10 stimulation of endothelial cell apoptosis may prevent tumor blood supply and cause tumor regression. See Dimmeler and Zeiher, *Cir. Res.*, 87:434-439 (2000). Dysregulation of apoptosis is also an integral part of a wide range of autoimmune diseases and disorders. See Ravirajan et al., *Int. Rev. Immunol.*, 18:563-589 (1999). In addition, many neurological disorders involve apoptosis. During adulthood, there is
15 little normal neuronal cell death. However, neurological diseases, particularly neurodegenerative diseases are often associated with excessive neural cell death. See Honig and Rosenberg, *Am. J. Med.*, 108:317-330 (2000). For example, Parkinson's disease is associated with the loss of substantia nigra pars compacta and sympathetic ganglia, while Alzheimer's disease is characterized with selective cell loss of entorhinal
20 neurons, and hippocampal neurons, cortical neurons. See Honig and Rosenberg, *Am. J. Med.*, 108:317-330 (2000).

Apoptosis also plays an important role in osteoporotic disorders including, but not limited to, postmenopausal osteoporosis, involutional osteoporosis, and glucocorticoid-induced osteoporosis. See Weinstein, et al., *Am. J. Med.*, 108:153-
25 164 (2000). Generally, under normal conditions, the balance between bone formation, bone resorption, bone cell proliferation and apoptosis maintains nearly constant bone mass. The imbalance of such processes leads to abnormal bone remodeling, and thus osteoporosis and other bone-related diseases. It has been suggested that treatment or prevention of osteoporosis may be achieved by promotion of osteoclast apoptosis and
30 prevention of osteoblast apoptosis. See Weinstein, et al., *Am. J. Med.*, 108:153-164 (2000).

Apoptosis also has physiological significance in animal virus infection. See Kyama et al., *Microbes and Infection*, 2:1111-1117 (2000). Apoptosis of cells

infected with viruses may slow the viral multiplication process, although animal viruses typically are able to escape apoptosis of the infected cells. However, it has been suggested that apoptosis of the infected cells triggers the phagocytosis of the dying cells by macrophages. This phagocytosis prevents the leakage of toxic substances that are
5 mediators of dysregulated inflammatory reactions. As a result, dysregulated inflammatory reactions are prevented while specific immune response against the viruses are initiated at the viral infection site. See Kyama et al., *Microbes and Infection*, 2:1111-1117 (2000). On the other hand, in the case of HIV infection, viral infection-induced apoptosis of CD4⁺ T cells contributes to the depletion of CD4⁺ T cells and
10 progression of HIV infection and AIDS, which is associated with immunodeficiency. Thus, inhibition of apoptosis of CD4⁺ T cells may be a strategy in preventing or treating HIV infection and AIDS. See Kirschner et al., *JAIDS J. Acq. Imm. Def. Syn.*, 24:352-362 (2000).

Additionally, apoptosis also plays a role in diseases such as ischemic
15 heart disease, stroke, and sepsis. For example, apoptosis-related neuronal cell death after cerebral ischemia may contribute to stroke. See Johnson et al., *J. Neurotrauma.*, 12:843-52 (1995). Thus, inhibition of apoptosis may be an approach in the development of therapeutic interventions of ischemic stroke. In addition, the inhibition of endothelial cell apoptosis may improve angiogenesis and vasculogenesis in patients with ischemia,
20 and thus may be an effective method for treating ischemia injuries. See Dimmeler and Zeiher, *Cir. Res.*, 87:434-439 (2000).

Thus, the methods can be applicable to a variety of tumors, i.e., abnormal growth, whether cancerous (malignant) or noncancerous (benign), and whether primary tumors or secondary tumors. Such disorders include but are not
25 limited to lung cancers such as bronchogenic carcinoma (e.g., squamous cell carcinoma, small cell carcinoma, large cell carcinoma, and adenocarcinoma), alveolar cell carcinoma, bronchial adenoma, chondromatous hamartoma (noncancerous), and sarcoma (cancerous); heart tumors such as myxoma, fibromas and rhabdomyomas; bone tumors such as osteochondromas, condromas, chondroblastomas,
30 chondromyxoid fibromas, osteoid osteomas, giant cell tumors, chondrosarcoma, multiple myeloma, osteosarcoma, fibrosarcomas, malignant fibrous histiocytomas, Ewing's tumor (Ewing's sarcoma), and reticulum cell sarcoma; brain tumors such as gliomas (e.g., glioblastoma multiforme), anaplastic astrocytomas, astrocytomas, and

oligodendrogliomas, medulloblastomas, chordoma, Schwannomas, ependymomas, meningiomas, pituitary adenoma, pinealoma, osteomas, and hemangioblastomas, craniopharyngiomas, chordomas, germinomas, teratomas, dermoid cysts, and angiomas; various oral cancers; tumors in digestive system such as leiomyoma, 5 epidermoid carcinoma, adenocarcinoma, leiomyosarcoma, stomach adenocarcinomas, intestinal lipomas, intestinal neurofibromas, intestinal fibromas, polyps in large intestine, familial polyposis such as Gardner's syndrome and Peutz-Jeghers syndrome, colorectal cancers (including colon cancer and rectal cancer); liver cancers such as hepatocellular adenomas, hemangioma, hepatocellular carcinoma, fibrolamellar 10 carcinoma, cholangiocarcinoma, hepatoblastoma, and angiosarcoma; kidney tumors such as kidney adenocarcinoma, renal cell carcinoma, hypernephroma, and transitional cell carcinoma of the renal pelvis; bladder cancers; tumors in blood system including acute lymphocytic (lymphoblastic) leukemia, acute myeloid (myelocytic, myelogenous, myeloblastic, myelomonocytic) leukemia, chronic 15 lymphocytic leukemia (e.g., Sezary syndrome and hairy cell leukemia), chronic myelocytic (myeloid, myelogenous, granulocytic) leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, mycosis fungoides, and myeloproliferative disorders (including myeloproliferative disorders are polycythemia vera, myelofibrosis, thrombocythemia, and chronic myelocytic leukemia); skin cancers such as basal cell 20 carcinoma, squamous cell carcinoma, melanoma, Kaposi's sarcoma, and Paget's disease; head and neck cancers; eye-related cancers such as retinoblastoma and intraocular melanocarcinoma; male reproductive system cancers such as benign prostatic hyperplasia, prostate cancer, and testicular cancers (e.g., seminoma, teratoma, embryonal carcinoma, and choriocarcinoma); breast cancer; female 25 reproductive system cancers such as uterus cancer (endometrial carcinoma), cervical cancer (cervical carcinoma), cancer of the ovaries (ovarian carcinoma), vulvar carcinoma, vaginal carcinoma, fallopian tube cancer, and hydatidiform mole; thyroid cancer (including papillary, follicular, anaplastic, or medullary cancer); pheochromocytomas (adrenal gland); noncancerous growths of the parathyroid 30 glands; cancerous or noncancerous growths of the pancreas; etc.

Specifically, breast cancers, colon cancers, prostate cancers, lung cancers and skin cancers may be amenable to the treatment by the methods of the present invention. In addition, premalignant conditions may also be treated by the

methods of the present invention to prevent or stop the progression of such conditions towards malignancy, or cause regression of the premalignant conditions. Examples of premalignant conditions include hyperplasia, dysplasia, and metaplasia.

Thus, the term "treating cancer" as used herein, specifically refers to
5 administering therapeutic agents to a patient diagnosed of cancer, i.e., having established cancer in the patient, to inhibit the further growth or spread of the malignant cells in the cancerous tissue, and/or to cause the death of the malignant cells. The term "treating cancer" also encompasses treating a patient having premalignant conditions to stop the progression of, or cause regression of, the
10 premalignant conditions.

The methods of the present invention may also be useful in treating or preventing other diseases and disorders caused by abnormal cell proliferation (hyperproliferation or dysproliferation), e.g., keloid, liver cirrhosis, psoriasis, etc. In addition, the methods may also find applications in promoting wound healing, and
15 other cell and tissue growth-related conditions.

The methods for modulating the expression levels of cell cycling and cell signaling proteins may be employed to modulate apoptosis and lipid metabolism. In addition, the methods may also be used in the treatment or prevention of diseases and disorders such as cancer, viral infection, AIDS, asthma, ischemia, stroke, autoimmune
20 diseases, neurodegenerative diseases, inflammatory disorders, sepsis, and osteoporosis.

In yet another embodiment, the methods for modulating the expression levels of cell cycling and/or cell signaling proteins may be used in treating or preventing autoimmune diseases and disorders including, but not limited to, rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjogren's syndrome, Canale-Smith syndrome, psoriasis, scleroderma, dermatomyositis, polymyositis, Behcet's syndrome, skin-related autoimmune diseases such as bullus pemphigoid, IgA dermatosis, pemphigus vulgaris, pemphigus foliaceus, dermatitis herpetiformis, contact dermatitis, autoimmune alopecia, erythema nodosa, and epidermolysis
25 bullous aquisita, drug-induced hemotologic autoimmune disorders, autoimmune thrombocytopenic purpura, autoimmune neutropenia, systemic sclerosis, multiple sclerosis, imflammatory demyelinating, diabetes mellitus, autoimmune polyglandular syndromes, vasculitides, Wegener's granulomatosis, Hashimoto's disease,
30

multinodular goitre, Grave's disease, autoimmune encephalomyelitis (EAE), demyelinating diseases, etc.

The methods of the present invention can also be useful in treating neurodegenerative disorders including, but not limited to, Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, brain trauma, infarction, hemorrhage, amyotrophic lateral sclerosis/Lou Gehrig's disease (ALS), inherited ataxias such as olivopontocerebellar atrophy (spinocerebellar ataxia type 1), and Machado-Joseph disease (spinocerebellar ataxia type 3).

BVR can be used for therapeutic interventions in neurodegenerative disorders as a method to promote neuronal cell growth or differentiation of uncommitted cells to neurons. BVR also can be used to control viral replication and oncogenesis.

The cell in which the nuclear or cellular concentration of BVR, or fragments or variants thereof, is to be modified can be located *in vivo* or *ex vivo*.

The nuclear or cellular concentration of BVR (or fragments or variants thereof) can be modified according to a number of approaches, either by delivering the BVR (or fragments or variants thereof) or antisense BVR RNA molecule into the cell in a manner which affords the protein or polypeptide or RNA molecule to be active within the cell or by delivering DNA encoding BVR (or fragments or variants thereof) or antisense BVR RNA molecule into the cell in a manner effective to induce the expression thereof in the cell. When BVR (or fragments or variants thereof) is delivered into target cells, it may be desirable that such delivery be effective to cause nuclear uptake of the BVR (or fragments or variants thereof). As noted above, BVR or fragments or variants contain the native BVR nuclear localization signal or a chimeric nuclear localization signal. When antisense BVR RNA is delivered into target cells, the antisense RNA is effective in the cytoplasm and need not be targeted to any particular location within the cytoplasm, although higher efficacy can be obtained when targeting the antisense BVR RNA to ribosomal sites.

One approach for delivering protein or polypeptides or RNA molecules into cells involves the use of liposomes. Basically, this involves providing a liposome which includes that protein or polypeptide or RNA to be delivered, and then contacting the target cell with the liposome under conditions effective for delivery of the protein or polypeptide or RNA into the cell.

Liposomes are vesicles comprised of one or more concentrically ordered lipid bilayers which encapsulate an aqueous phase. They are normally not leaky, but can become leaky if a hole or pore occurs in the membrane, if the membrane is dissolved or degrades, or if the membrane temperature is increased to the phase transition temperature. Current methods of drug delivery via liposomes require that the liposome carrier ultimately become permeable and release the encapsulated drug at the target site. This can be accomplished, for example, in a passive manner wherein the liposome bilayer degrades over time through the action of various agents in the body. Every liposome composition will have a characteristic half-life in the circulation or at other sites in the body and, thus, by controlling the half-life of the liposome composition, the rate at which the bilayer degrades can be somewhat regulated.

In contrast to passive drug release, active drug release involves using an agent to induce a permeability change in the liposome vesicle. Liposome membranes can be constructed so that they become destabilized when the environment becomes acidic near the liposome membrane (see, e.g., *Proc. Natl. Acad. Sci. USA* 84:7851 (1987); *Biochemistry* 28:908 (1989), each of which is hereby incorporated by reference in its entirety). When liposomes are endocytosed by a target cell, for example, they can be routed to acidic endosomes which will destabilize the liposome and result in drug release.

Alternatively, the liposome membrane can be chemically modified such that an enzyme is placed as a coating on the membrane, which enzyme slowly destabilizes the liposome. Since control of drug release depends on the concentration of enzyme initially placed in the membrane, there is no real effective way to modulate or alter drug release to achieve "on demand" drug delivery. The same problem exists for pH-sensitive liposomes in that as soon as the liposome vesicle comes into contact with a target cell, it will be engulfed and a drop in pH will lead to drug release.

This liposome delivery system can also be made to accumulate at a target organ, tissue, or cell via active targeting (e.g., by incorporating an antibody or hormone on the surface of the liposomal vehicle). This can be achieved according to known methods.

Different types of liposomes can be prepared according to Bangham et al., *J. Mol. Biol.* 13:238-252 (1965); U.S. Patent No. 5,653,996 to Hsu et al.; U.S. Patent No. 5,643,599 to Lee et al.; U.S. Patent No. 5,885,613 to Holland et al.; U.S.

Patent No. 5,631,237 to Dzau et al.; and U.S. Patent No. 5,059,421 to Loughrey et al., each of which is hereby incorporated by reference in its entirety.

5 An alternative approach for delivery of proteins or polypeptides involves the conjugation of the desired protein or polypeptide to a polymer that is stabilized to avoid enzymatic degradation of the conjugated protein or polypeptide. Conjugated proteins or polypeptides of this type are described in U.S. Patent No. 5,681,811 to Ekwuribe, which is hereby incorporated by reference in its entirety.

10 Yet another approach for delivery of proteins or polypeptides involves preparation of chimeric proteins according to U.S. Patent No. 5,817,789 to Heartlein et al., which is hereby incorporated by reference in its entirety. The chimeric protein can include a ligand domain and, e.g., BVR or a fragment or variant thereof as described above. The ligand domain is specific for receptors located on a target cell. Thus, when the chimeric protein is delivered intravenously or otherwise introduced into blood or lymph, the chimeric protein will adsorb to the targeted cell, and the targeted cell will
15 internalize the chimeric protein.

When it is desirable to achieve heterologous expression of a desirable protein or polypeptide or RNA molecule in a target cell, DNA molecules encoding the desired protein or polypeptide or RNA can be delivered into the cell. Basically, this includes providing a nucleic acid molecule encoding the protein or polypeptide and
20 then introducing the nucleic acid molecule into the cell under conditions effective to express the protein or polypeptide or RNA in the cell. Preferably, this is achieved by inserting the nucleic acid molecule into an expression vector before it is introduced into the cell.

When transforming mammalian cells for heterologous expression of a
25 protein or polypeptide, an adenovirus vector can be employed. Adenovirus gene delivery vehicles can be readily prepared and utilized given the disclosure provided in Berkner, *Biotechniques* 6:616-627 (1988) and Rosenfeld et al., *Science* 252:431-434 (1991), WO 93/07283, WO 93/06223, and WO 93/07282, each of which is hereby incorporated by reference in its entirety. Adeno-associated viral gene delivery vehicles
30 can be constructed and used to deliver a gene to cells. The use of adeno-associated viral gene delivery vehicles *in vitro* is described in Chatterjee et al., *Science* 258:1485-1488 (1992); Walsh et al., *Proc. Nat'l. Acad. Sci. USA* 89:7257-7261 (1992); Walsh et al., *J. Clin. Invest.* 94:1440-1448 (1994); Flotte et al., *J. Biol. Chem.* 268:3781-3790

(1993); Ponnazhagan et al., *J. Exp. Med.* 179:733-738 (1994); Miller et al., *Proc. Nat'l Acad. Sci. USA* 91:10183-10187 (1994); Einerhand et al., *Gene Ther.* 2:336-343 (1995); Luo et al., *Exp. Hematol.* 23:1261-1267 (1995); and Zhou et al., *Gene Ther.* 3:223-229 (1996), each of which is hereby incorporated by reference in its entirety. *In vivo* use of these vehicles is described in Flotte et al., *Proc. Nat'l Acad. Sci. USA* 90:10613-10617 (1993); and Kaplitt et al., *Nature Genet.* 8:148-153 (1994), each of which is hereby incorporated by reference in its entirety. Additional types of adenovirus vectors are described in U.S. Patent No. 6,057,155 to Wickham et al.; U.S. Patent No. 6,033,908 to Bout et al.; U.S. Patent No. 6,001,557 to Wilson et al.; U.S. Patent No. 5,994,132 to Chamberlain et al.; U.S. Patent No. 5,981,225 to Kochanek et al.; and U.S. Patent No. 5,885,808 to Spooner et al.; and U.S. Patent No. 5,871,727 to Curiel, each of which is hereby incorporated by reference in its entirety).

Retroviral vectors which have been modified to form infective transformation systems can also be used to deliver nucleic acid encoding a desired protein or polypeptide or RNA product into a target cell. One such type of retroviral vector is disclosed in U.S. Patent No. 5,849,586 to Kriegler et al., which is hereby incorporated by reference in its entirety.

Regardless of the type of infective transformation system employed, it should be targeted for delivery of the nucleic acid to a specific cell type. For example, for delivery of the nucleic acid into a cluster of cells, a high titer of the infective transformation system can be injected directly within the site of those cells so as to enhance the likelihood of cell infection. The infected cells will then express the desired product, in this case BVR (or fragments or variants thereof) or antisense BVR RNA, to modify the expression of cell cycle or cell signaling proteins.

Whether the proteins or polypeptides or nucleic acids are administered alone or in combination with pharmaceutically or physiologically acceptable carriers, excipients, or stabilizers, or in solid or liquid form such as, tablets, capsules, powders, solutions, suspensions, or emulsions, they can be administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, by application to mucous membranes, such as, that of the nose, throat, and bronchial tubes, or by transdermal delivery. For most therapeutic purposes, the proteins or polypeptides or nucleic acids can be administered intravenously.

For injectable dosages, solutions or suspensions of these materials can be prepared in a physiologically acceptable diluent with a pharmaceutical carrier. Such carriers include sterile liquids, such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable carrier, including
5 adjuvants, excipients or stabilizers. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solution, and glycols, such as propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions.

10 For use as aerosols, the proteins or polypeptides or nucleic acids in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. The materials of the present invention also may be administered in a non-pressurized form such as in a nebulizer or atomizer.

15 Both the biliverdin reductase, or fragment or variant thereof, and the antisense RNA can be delivered to the target cells (i.e., at or around the site of the stroke/ischemic event) using the above-described methods for delivering such therapeutic products. In delivering the therapeutic products to nerve cells in the brain, consideration should be provided to negotiation of the blood-brain barrier. The blood-
20 brain barrier typically prevents many compounds in the blood stream from entering the tissues and fluids of the brain. Nature provides this mechanism to insure a toxin-free environment for neurologic function. However, it also prevents delivery to the brain of therapeutic compounds.

One approach for negotiating the blood-brain barrier is described in U.S.
25 Patent No. 5,752,515 to Jolesz et al., which is hereby incorporated by reference in its entirety. Basically, the blood-brain barrier is temporarily "opened" by targeting a selected location in the brain and applying ultrasound to induce, in the central nervous system (CNS) tissues and/or fluids at that location, a change detectable by imaging. A protein or polypeptide or RNA molecule of the present invention can delivered to the
30 targeted region of the brain while the blood-brain barrier remains "open," allowing targeted neuronal cells to uptake the delivered protein or polypeptide or RNA. At least a portion of the brain in the vicinity of the selected location can be imaged, e.g., via magnetic resonance imaging, to confirm the location of the change. Alternative

approaches for negotiating the blood-brain barrier include chimeric peptides and modified liposome structures which contain a PEG moiety (reviewed in Pardridge, *J. Neurochem.* 70:1781-1792 (1998), which is hereby incorporated by reference in its entirety), as well as osmotic opening (i.e., with bradykinin, mannitol, RPM7, etc.) and
5 direct intracerebral infusion (Kroll et al., *Neurosurgery* 42(5):1083-1100 (1998), which is hereby incorporated by reference in its entirety.

EXAMPLES

10 The following examples are provided to illustrate embodiments of the present invention, but they are by no means intended to limit its scope.

Example 1 - Microarray Analysis of Cell Cycle and Cell Signaling Proteins Following BVR Expression in HEK Cells

15 The structure of the coding and the non-coding constructs are illustrated in Figure 1. 16h after transfection there was a significant increase in hBVR expression that reached a prominent peak at 24h after transfection. The Western blot analysis of protein expression is shown in Figure 2. Analysis of percent of cells in
20 G1/G0 phase at 18h and 24h, respectively, resulted in the following data: 31% and 21% when transfected with the reverse construct, 50% and 48% when transected with the wild-type BVR construct. Because the G1/G0 is the quiescence phase in cell cycle, i.e., when DNA repair takes place, an increase in duration of the phase is considered a protective cell response. The results of the gene array analysis showed
25 increase in mRNA levels for several kinases and transcription factors that control cell cycle transition. The increases measured up to 30-fold were found in: ATF-2/CREB (activating transcription factor-2, cAMP response element binding protein), cyclinA, cyclinE, and E2F-3. Others also demonstrated significant increases in expression levels. Notably, mRNA levels for cytochrome P450 aromatase, an enzyme
30 responsible for estrogen biosynthesis, was increase by over 30-fold. Transcription of this gene is regulated through cAMP regulatory element. Western blot analysis revealed that in fact ATF-2 protein is significantly increased in cells transfected with HBVR at 16 h and 24 h after transfection (see Figure 3).

In hBVR transfected cells, gene array analysis show altered expression of several other cell cycle enzymes and regulators including Cdc25a. Cdc25a mRNA is increased by over 20-fold. This cell division enzyme activates Cdc2Cyclin B complex formation that induces meiotic metaphase. These studies show that hBVR
5 interact with chromatin as cell divides (see Figure 4).

Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and
10 scope of the invention which is defined by the following claims.

Each of the references cited in the present application is intended to be incorporated herein in its entirety by reference to the same.

TABLE 1

Gene name	Inverted	Virus	S-44	WT	
Alpha-2-macroglobulin	0.33	0.44	-	-	
creb-2	24.33	19.88	103.83	204.37	
bax	251.00	75.44	108.33	123.37	
bcl-2	0.33	0.19	0.17	1.13	
bfl-1	1.33	0.19	-	4.13	
bcl-xl	18.67	6.56	16.17	23.25	
NAIP/BIRC1	-	1.06	1.50	2.25	
IAP-2	42.00	15.75	78.33	110.25	
IAP-1	24.00	5.69	31.17	37.50	
BMP2	0.67	0.38	0.17	0.38	
BMP 4	0.33	0.88	0.33	-	
BRCA1	5.33	2.69	4.83	4.88	
cyclin D1	0.33	0.31	0.33	-	
CD5	0.33	0.38	0.33	0.38	
cdk2	199.33	30.75	141.00	217.12	
p21/ Waf1/Cip1	1.00	0.75	0.33	0.75	
p27Kip1	1.00	0.25	0.17	0.38	
p57Kip2	-	0.31	0.17	1.50	
p16ink4	208.00	71.38	213.83	307.88	
p15 Ink2b	1.00	0.44	1.00	0.38	
p18 (cdk4 inhibitor)	1.33	0.75	0.33	0.75	
p19Ink4d	27.33	6.00	21.17	18.38	
CDX1	1.00	0.56	0.83	0.38	
C/EBP beta	0.67	0.31	-	0.38	
GM-CSF	-	1.63	-	-	
beta-casein	16.33	6.50	28.67	150.00	
cathepsin D	2.67	1.63	1.50	0.75	
p450XIX	1.00	0.69	4.33	36.00	
EGFR	0.67	1.88	2.83	2.25	
egr-1	65.67	10.63	59.33	86.25	
engrailed homolog 1	0.67	0.50	0.17	-	
FASN	2.67	1.13	1.67	0.38	
Stra6	16.00	1.00	10.33	1.87	
fibronectin-1	262.67	53.00	225.50	299.63	
c-fos	0.33	0.44	-	-	
GADD45	1.67	2.06	6.67	12.75	
Glycogen Synthase	0.67	0.94	0.83	1.50	
HIP	5.00	1.88	12.67	22.50	
Hexokinase II	2.33	1.81	0.33	1.87	
Forkhead box A2	46.33	6.13	41.33	19.13	
Hoxa-1	2.33	0.13	0.33	-	
Hoxb-1	7.33	1.69	2.33	2.63	

TABLE 1 cont.

hsf1/tcf5	1.00	1.19	2.00	7.50
Hsp27	12.67	11.75	19.00	43.50
hsp90/CDw52	944.00	375.81	1,248.17	2,336.63
ICAM-1	1.00	1.63	0.67	1.50
IGFBP-3	1.33	0.50	0.33	0.75
IL-2	-	0.75	0.17	-
IL-2 Ra	0.67	0.19	0.17	0.38
IL-4	-	0.19	-	-
IL-4 Ra	1.00	0.38	-	-
IRF-1	0.67	0.94	1.00	-
c-jun	1.00	2.38	2.67	3.75
jun-B	-	2.06	0.33	0.38
hGK2	-	0.56	0.33	-
PSA	-	0.50	0.17	-
Leptin	0.33	0.19	-	-
TNF-b/Lta	2.67	0.81	1.00	0.38
mdm2	101.33	31.63	76.67	87.75
MIG	0.33	0.88	0.17	-
MMP10	0.33	0.75	0.50	0.38
MMP-7	-	0.25	-	0.38
c-myc	4.00	5.69	4.00	6.37
NFkB	1.67	2.38	11.50	3.37
IkBα/mad3	0.67	0.38	0.50	0.75
iNOS	25.33	14.19	13.33	21.38
ornithine decarboxylase	4,389.67	682.69	2,139.00	5,293.13
CD31/E-CAM-1	8.67	9.25	4.67	31.87
PR	0.33	0.31	-	0.38
PIG3	6.00	2.19	7.33	6.75
PKC alpha	8.00	12.06	19.83	19.13
PKC beta	-	1.25	0.17	-
PKCE	0.67	0.13	0.17	-
Patched 1	1.33	1.00	1.17	0.75
Patched 2	5.33	3.63	7.83	6.00
Cox-2	0.33	0.31	0.33	0.75
CRBPI	0.33	0.44	-	-
CRABPII	0.33	0.50	-	0.75
Mcp-1	-	1.00	-	-
ELAM-1/E-selectin	-	0.69	0.17	0.38
P-selectin	-	0.38	0.33	0.38
WSB1/SWIP-1	452.33	144.69	256.83	548.63
TFRC	43.67	19.31	79.83	123.00
PMEPA1	-	0.13	0.17	-
TNF-a	-	0.13	0.17	-

TABLE 1 cont.

Trail Receptor /DR5	65.33	4.38	16.33	6.00
Fas/Apo-1/ CD95	0.33	1.50	1.83	0.38
Fas ligand	0.33	0.50	-	-
p53	0.33	-	-	-
VCAM-1	-	0.06	0.33	0.38
WISP1	0.33	0.13	0.33	-
WISP2	-	0.31	0.17	-
WISP3	0.67	0.88	0.33	1.50
Wnt1	398.33	79.56	182.33	387.75
WNT2	15.00	5.19	7.67	9.00
EFP	9.00	2.75	4.67	7.50
pUC18	1.33	0.90	1.61	0.88
0	5.33	9.17	4.06	9.25
GAPDH	4,162.83	908.06	2,255.00	4,736.81
cyclophilin A	831.58	234.30	544.38	1,001.72
RPL13A	12.33	7.31	16.50	6.94
b-actin	207.00	59.78	113.92	134.25

Filter Filter Filter Filter

cell cycle

TABLE 2

Gene name	virus	inverted	wt	s-44
c-abl	0.08	0.40	-	-
Apaf-1	0.08	1.20	-	-
ATM	0.32	0.40	-	-
bax	3.20	0.40	0.60	4.44
bcl-2	-	-	-	-
BRCA1	0.40	1.20	-	0.67
cyclin A1	0.56	-	0.40	-
cyclin A	9.12	8.00	28.40	45.78
cyclin B	2.24	18.60	12.80	4.00
cyclin B2	1.28	7.80	4.80	1.56
cyclin C	3.92	16.00	13.60	16.44
cyclin D1	0.08	0.20	-	-
cyclin D2	0.16	-	-	-
cyclin D3	8.32	0.20	0.20	1.11
cyclin E1	6.80	6.80	27.00	23.56
cyclin E2	2.64	2.60	9.20	9.11
cyclin F	3.04	0.20	0.20	-
cyclin G	7.12	32.80	17.00	29.78
cyclin G2	0.56	0.20	0.40	0.22
cyclin H	0.24	0.20	-	-
Cdc16	0.88	1.00	0.60	1.56
cdk1 (cdc2)	140.56	322.60	416.80	511.56
P55cdc (CDC20)	1.04	1.00	2.60	0.44
CDC25a, phosphatase	9.36	2.80	44.40	40.67
Cdc27	148.08	534.00	426.40	342.44
CDC34	0.24	0.60	0.20	0.22
CDC37	-	0.40	0.40	-
CDC45-DNA like1	0.24	0.20	0.60	-
CDC6	12.72	36.80	58.00	39.78
CDC7	4.40	7.80	3.80	13.78
cdk2	24.96	8.20	40.40	36.89
cdk4	7.76	1.00	4.00	3.56
cdk6	-	0.20	-	-
CDK7	0.16	0.80	1.20	0.89
CDK8	0.32	2.00	2.80	3.56
p21Waf1 (p21Cip1)	-	-	0.20	-
p27Kip1	0.32	-	0.40	-
p57Kip2	0.24	-	1.00	-
p16Ink4	65.04	146.40	168.60	271.78
p15 Ink2b	0.56	-	0.40	-
p18 (cdk4 inhibitor)	0.08	0.20	0.20	-
p19Ink4d	0.08	-	2.40	-
chk1	0.72	5.00	4.00	4.44
Cks1p9	33.36	97.80	127.20	124.00
CKS2	0.96	4.00	9.00	5.56
Cul1	4.96	0.20	21.40	22.22

TABLE 2 cont.

Cullin-Cul2	10.24	16.40	21.60	30.67
Cullin-Cul3	21.36	34.80	48.40	69.78
Cullin-Cul4A	-	-	0.20	-
Cullin-Cul4B	0.56	6.40	2.80	2.89
Cullin-Cul5	0.24	1.40	1.00	1.11
E2F	0.08	0.40	-	-
E2F-2	0.32	0.40	-	-
E2F-3	1.84	0.80	10.80	4.00
E2F-4	0.40	-	0.40	-
E2F-5	0.96	-	0.40	0.44
E2F-6	1.20	1.20	1.40	0.44
MPP2	0.16	0.80	0.40	0.22
GADD45	0.40	1.00	0.40	-
Hus1	0.48	0.20	0.40	-
MAD2L1	6.16	12.60	23.20	21.78
MAD2L2	2.64	-	-	0.44
MCM2	0.64	-	-	-
MCM3	15.52	0.60	12.80	17.78
MCM4 (CDC21)	0.32	3.40	2.60	1.11
MCM5(CDC46),	-	1.00	-	-
MCM6(Mis5),	40.08	69.80	177.60	89.78
MCM7(cdc47)	12.08	3.40	16.40	6.89
mdm2	16.32	31.20	28.40	30.89
Ki67(MKI67)	2.08	0.60	0.60	2.00
MRE11A	8.72	7.60	8.80	11.33
MRE11B	4.48	3.00	5.60	3.11
nibrin	0.16	1.20	0.20	0.22
Nedd8	11.20	42.40	26.80	30.89
PCNA	0.64	0.20	1.40	0.67
PRC1	9.36	22.20	39.20	21.56
RAD17	0.32	-	-	-
RAD50	2.64	3.20	0.20	4.89
RAD51	2.32	0.40	0.60	1.33
chk2 (RAD53)	391.28	748.60	688.40	676.00
RAD9	-	-	0.40	-
Rb	0.16	-	0.20	-
p107	0.64	0.80	0.60	-
p130 (RB2)	0.32	-	-	-
Rbx1	24.00	5.80	50.20	56.22
rpa	1.52	2.00	-	0.67
skp1	11.52	17.80	3.80	20.67
skp2	42.24	72.40	40.20	78.00
DP1	0.48	0.40	0.40	-
DP2	1.04	2.00	1.00	-
TIMP3	0.16	-	-	-
p53	0.16	-	-	-
ubiquitin C	0.08	-	-	-

TABLE 2 cont.

UBE1	16.48	23.00	22.00	20.44
E6-AP	4.32	2.60	3.00	3.78
SUMO-1 ub (sentrin)	23.04	28.80	34.20	43.56
pUC18	0.96	-	-	-
0	0.32	-	-	-
GAPDH	235.96	288.20	287.20	368.00
cyclophilin A	188.88	217.00	301.90	279.44
RPL13A	4.56	1.40	5.70	0.44
b-actin	36.60	26.10	38.80	77.00
	Filter	Filter	Filter	Filter




Fig. 1




FIG. 2






Fig. 3

Association of BVR with Chromatin



BVR UV



BVR Heme treatment

Fig 4

What is Claimed:

1. A method of modifying expression of cell cycle or cell signaling proteins comprising:
 - 5 modifying the nuclear or cellular concentration of biliverdin reductase, or fragments or variants thereof, in a cell, whereby a change in the nuclear concentration of biliverdin reductase, or fragments or variants thereof, modifies the transcription of cell cycle or cell signaling proteins.
- 10 2. The method according to claim 1 wherein said modifying comprises:
 - transforming the cell with a DNA construct which expresses antisense biliverdin reductase RNA in the cell, said transforming decreasing the nuclear or cellular concentration of biliverdin reductase.
- 15 3. The method according to claim 1 wherein said modifying comprises:
 - transforming the cell with a DNA construct which expresses biliverdin reductase or fragments or variants thereof in the cell, said transforming increasing the
 - 20 nuclear or cellular concentration of biliverdin reductase or fragments or variants thereof.
- 25 4. The method according to claim 1 wherein said modifying comprises:
 - introducing biliverdin reductase or fragments or variants thereof into the cell.
- 30 5. The method according to claim 4 wherein said introducing comprises:
 - contacting the cell with a delivery vehicle comprising biliverdin reductase or fragments or variants thereof under conditions effective to induce cellular uptake of at least the biliverdin reductase or fragments or variants thereof.

6. The method according to claim 5 wherein the delivery vehicle is a liposome comprising biliverdin reductase or fragments or variants thereof.

7. The method according to claim 5 wherein the delivery vehicle is a fusion protein comprising biliverdin reductase or fragments or variants thereof.

8. The method according to claim 1 wherein the cell is *ex vivo*.

9. The method according to claim 1 wherein the cell is *in vivo*.

10. The method according to claim 1 wherein the cell signal protein is selected from the group consisting of creb-2, bax, bfl-1, IAP-1, IAP-2, p16Ink4, beta-casein, p450XIX, GADD45, HIP, p27Kip1, p15Ink2b, p18 (cdk4 inhibitor), CDX1, FASN, Stra6.

11. The method according to claim 1 wherein the cell cycling protein is selected from the group consisting of cyclins A, E1 and E2, CDK15a, CDC7, cdk1, cdk2, cdk8, Cks2, Cks1p9, Cul1, Cul2, Cul3, E2F-3, MAD2L1, MCM6, Rbx1, RAD50, cdk4, CDK10, and RPL13A.